Trial Outcomes & Findings for A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants (NCT NCT04263142)

Results Overview

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were calculated using standard non-compartmental analysis.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

39 participants

Primary outcome timeframe

pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Results posted on

2021-03-03

Participant Flow

This was a 2-part, randomized, single dose cross-over study conducted at a single center in the United States to assess the relative bioavailability and food effect of GSK3640254 tablet and capsule formulations in healthy participants.

A total of 39 participants were enrolled in Part 1 (18 participants) and Part 2 (21 participants) of the study.

Participant milestones

Participant milestones
Measure	Part 1: Treatment Sequence AB Participants were administered a single dose of GSK3640254 200 milligram (mg) capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg tablets (Treatment B- test), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 1: Treatment Sequence BA Participants were administered a single dose of GSK3640254 200 mg tablets (Treatment B-test), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence CDE Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence DEC Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence ECD Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 1; followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 2; followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.
Part 1 Period 1 (Day 1) STARTED	9	9	0	0	0
Part 1 Period 1 (Day 1) COMPLETED	9	9	0	0	0
Part 1 Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0
Part 1 Period 2 (Up to Day 5) STARTED	9	9	0	0	0
Part 1 Period 2 (Up to Day 5) COMPLETED	9	9	0	0	0
Part 1 Period 2 (Up to Day 5) NOT COMPLETED	0	0	0	0	0
Part 2 Period 1 (Day 1) STARTED	0	0	7	7	7
Part 2 Period 1 (Day 1) COMPLETED	0	0	7	7	6
Part 2 Period 1 (Day 1) NOT COMPLETED	0	0	0	0	1
Part 2 Period 2 (Day 1) STARTED	0	0	7	7	6
Part 2 Period 2 (Day 1) COMPLETED	0	0	7	7	5
Part 2 Period 2 (Day 1) NOT COMPLETED	0	0	0	0	1
Part 2 Period 3 (Up to Day 5) STARTED	0	0	7	7	5
Part 2 Period 3 (Up to Day 5) COMPLETED	0	0	7	7	5
Part 2 Period 3 (Up to Day 5) NOT COMPLETED	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Treatment Sequence AB Participants were administered a single dose of GSK3640254 200 milligram (mg) capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg tablets (Treatment B- test), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 1: Treatment Sequence BA Participants were administered a single dose of GSK3640254 200 mg tablets (Treatment B-test), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence CDE Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence DEC Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence ECD Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 1; followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 2; followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.
Part 2 Period 1 (Day 1) Adverse Event	0	0	0	0	1
Part 2 Period 2 (Day 1) Physician Decision	0	0	0	0	1

Baseline Characteristics

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Treatment Sequence AB n=9 Participants Participants were administered a single dose of GSK3640254 200 milligram (mg) capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg tablets (Treatment B- test), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 1: Treatment Sequence BA n=9 Participants Participants were administered a single dose of GSK3640254 200 mg tablets (Treatment B-test), orally under moderate fat conditions on Day 1 in Period 1, followed by GSK3640254 200 mg capsules (Treatment A-reference), orally under moderate fat conditions on Day 1 in Period 2. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence CDE n=7 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence DEC n=7 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 1, followed by GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 2, followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Part 2: Treatment Sequence ECD n=7 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions (Treatment E-test) on Day 1 in Period 1; followed by GSK3640254 200 mg tablets, orally under moderate fat conditions (Treatment C-test) on Day 1 in Period 2; followed by GSK3640254 200 mg tablets, orally under fasted conditions (Treatment D-reference) on Day 1 in Period 3. There was a wash out period of at least 7 days between each dose of study intervention.	Total n=39 Participants Total of all reporting groups
Age, Customized <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Age, Customized 19 to 64 years	9 Participants n=5 Participants	9 Participants n=7 Participants	7 Participants n=5 Participants	7 Participants n=4 Participants	7 Participants n=21 Participants	39 Participants n=10 Participants
Age, Customized >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	5 Participants n=21 Participants	14 Participants n=10 Participants
Sex: Female, Male Male	7 Participants n=5 Participants	6 Participants n=7 Participants	4 Participants n=5 Participants	6 Participants n=4 Participants	2 Participants n=21 Participants	25 Participants n=10 Participants
Race/Ethnicity, Customized American Indian or Alaskan Native	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized Black or African American	4 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	4 Participants n=21 Participants	15 Participants n=10 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized White-Arabic/North African Heritage	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized White-White/Caucasian/European Heritage	4 Participants n=5 Participants	5 Participants n=7 Participants	4 Participants n=5 Participants	5 Participants n=4 Participants	3 Participants n=21 Participants	21 Participants n=10 Participants

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population comprised of all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0 to Inf]) for GSK3640254-Part 1	36.94 Hours*microgram per milliliter Geometric Coefficient of Variation 42.7	36.88 Hours*microgram per milliliter Geometric Coefficient of Variation 40.3	—

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Time t (AUC[0 to t]) for GSK3640254-Part 1	33.72 Hours*microgram per milliliter Geometric Coefficient of Variation 41.1	33.80 Hours*microgram per milliliter Geometric Coefficient of Variation 40.2	—

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Maximum Observed Concentration (Cmax) for GSK3640254-Part 1	1.201 Microgram per milliliter Geometric Coefficient of Variation 33.4	1.313 Microgram per milliliter Geometric Coefficient of Variation 45.3	—

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Time of Maximum Observed Concentration for GSK3640254-Part 1	5.000 Hours Interval 3.0 to 12.0	4.000 Hours Interval 2.5 to 6.0	—

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
AUC(0 to Inf) for GSK3640254-Part 2	41.00 Hours*micrograms per milliliter Geometric Coefficient of Variation 42.2	13.46 Hours*micrograms per milliliter Geometric Coefficient of Variation 58.2	36.92 Hours*micrograms per milliliter Geometric Coefficient of Variation 35.9

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
AUC(0 to t) for GSK3640254-Part 2	37.91 Hours*micrograms per milliliter Geometric Coefficient of Variation 41.5	11.37 Hours*micrograms per milliliter Geometric Coefficient of Variation 65.6	34.08 Hours*micrograms per milliliter Geometric Coefficient of Variation 34.9

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Cmax for GSK3640254-Part 2	1.425 Micrograms per milliliter Geometric Coefficient of Variation 35.6	0.3544 Micrograms per milliliter Geometric Coefficient of Variation 84.4	1.082 Micrograms per milliliter Geometric Coefficient of Variation 38.6

PRIMARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Time of Maximum Observed Concentration for GSK3640254-Part 2	5.000 Hours Interval 2.0 to 8.0	4.000 Hours Interval 2.03 to 24.0	5.000 Hours Interval 1.5 to 12.0

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety Population comprised of all participants who received at least 1 dose of study medication.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 AEs	0 Participants	1 Participants	—
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 SAEs	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Up to Day 19

Population: Safety Population

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Number of Participants With AEs and SAEs-Part 2 AEs	0 Participants	0 Participants	5 Participants
Number of Participants With AEs and SAEs-Part 2 SAEs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Erythrocytes Count-Part 1 Baseline; n=18, 18	4.801 10^12 cells per liter Standard Deviation 0.4605	4.801 10^12 cells per liter Standard Deviation 0.4605	—
Absolute Values for Erythrocytes Count-Part 1 Day 2; n=18, 18	4.937 10^12 cells per liter Standard Deviation 0.4896	4.983 10^12 cells per liter Standard Deviation 0.5010	—
Absolute Values for Erythrocytes Count-Part 1 Day 5; n=9, 9	5.009 10^12 cells per liter Standard Deviation 0.4786	5.061 10^12 cells per liter Standard Deviation 0.3888	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Hemoglobin-Part 1 Day 5; n=9, 9	150.3 Grams per liter Standard Deviation 15.74	150.3 Grams per liter Standard Deviation 13.13	—
Absolute Values for Hemoglobin-Part 1 Baseline; n=18, 18	142.2 Grams per liter Standard Deviation 13.46	142.2 Grams per liter Standard Deviation 13.46	—
Absolute Values for Hemoglobin-Part 1 Day 2; n=18, 18	146.4 Grams per liter Standard Deviation 13.74	148.3 Grams per liter Standard Deviation 14.29	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Hematocrit-Part 1 Baseline; n=18, 18	0.4252 Proportion of red blood cells in blood Standard Deviation 0.03485	0.4252 Proportion of red blood cells in blood Standard Deviation 0.03485	—
Absolute Values for Hematocrit-Part 1 Day 2; n=18, 18	0.4346 Proportion of red blood cells in blood Standard Deviation 0.03935	0.4405 Proportion of red blood cells in blood Standard Deviation 0.03885	—
Absolute Values for Hematocrit-Part 1 Day 5; n=9, 9	0.4410 Proportion of red blood cells in blood Standard Deviation 0.04004	0.4430 Proportion of red blood cells in blood Standard Deviation 0.03266	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 1 Baseline; n=18, 18	88.80 Femtoliters Standard Deviation 4.887	88.80 Femtoliters Standard Deviation 4.887	—
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 1 Day 2; n=18, 18	88.21 Femtoliters Standard Deviation 4.480	88.61 Femtoliters Standard Deviation 4.363	—
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 1 Day 5; n=9, 9	88.17 Femtoliters Standard Deviation 4.532	87.63 Femtoliters Standard Deviation 4.971	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Baseline; n=18, 18	29.68 Picograms Standard Deviation 1.858	29.68 Picograms Standard Deviation 1.858	—
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 2; n=18, 18	29.69 Picograms Standard Deviation 1.740	29.83 Picograms Standard Deviation 1.772	—
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 5; n=9, 9	30.08 Picograms Standard Deviation 1.737	29.74 Picograms Standard Deviation 1.938	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Erythrocytes Count-Part 2 Baseline; n=20, 19, 21	4.613 10^12 cells per liter Standard Deviation 0.5680	4.613 10^12 cells per liter Standard Deviation 0.5680	4.613 10^12 cells per liter Standard Deviation 0.5680
Absolute Values for Erythrocytes Count-Part 2 Day 2; n=20, 19, 21	4.893 10^12 cells per liter Standard Deviation 0.5814	4.899 10^12 cells per liter Standard Deviation 0.5878	4.850 10^12 cells per liter Standard Deviation 0.5900
Absolute Values for Erythrocytes Count-Part 2 Day 5; n=7, 5, 7	4.941 10^12 cells per liter Standard Deviation 0.6086	4.424 10^12 cells per liter Standard Deviation 0.6683	4.957 10^12 cells per liter Standard Deviation 0.6309

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Hemoglobin-Part 2 Baseline; n=20, 19, 21	134.0 Grams per liter Standard Deviation 15.37	134.0 Grams per liter Standard Deviation 15.37	134.0 Grams per liter Standard Deviation 15.37
Absolute Values for Hemoglobin-Part 2 Day 2; n=20, 19, 21	140.6 Grams per liter Standard Deviation 15.83	141.1 Grams per liter Standard Deviation 16.19	140.0 Grams per liter Standard Deviation 15.37
Absolute Values for Hemoglobin-Part 2 Day 5; n=7, 5, 7	146.9 Grams per liter Standard Deviation 14.14	124.2 Grams per liter Standard Deviation 15.74	142.7 Grams per liter Standard Deviation 14.42

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Hematocrit-Part 2 Baseline; n=20, 19, 21	0.4010 Proportion of red blood cells in blood Standard Deviation 0.03876	0.4010 Proportion of red blood cells in blood Standard Deviation 0.03876	0.4010 Proportion of red blood cells in blood Standard Deviation 0.03876
Absolute Values for Hematocrit-Part 2 Day 2; n=20, 19, 21	0.4207 Proportion of red blood cells in blood Standard Deviation 0.03989	0.4219 Proportion of red blood cells in blood Standard Deviation 0.04146	0.4176 Proportion of red blood cells in blood Standard Deviation 0.03777
Absolute Values for Hematocrit-Part 2 Day 5; n=7, 5, 7	0.4337 Proportion of red blood cells in blood Standard Deviation 0.03499	0.3786 Proportion of red blood cells in blood Standard Deviation 0.04858	0.4216 Proportion of red blood cells in blood Standard Deviation 0.03917

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 2 Baseline; n=20, 19, 21	86.98 Femtoliters Standard Deviation 5.931	86.98 Femtoliters Standard Deviation 5.931	86.98 Femtoliters Standard Deviation 5.931
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 2 Day 2; n=20, 19, 21	86.37 Femtoliters Standard Deviation 5.934	86.52 Femtoliters Standard Deviation 6.038	86.57 Femtoliters Standard Deviation 5.867
Absolute Values for Erythrocyte Mean Corpuscular Volume-Part 2 Day 5; n=7, 5, 7	88.47 Femtoliters Standard Deviation 8.285	85.86 Femtoliters Standard Deviation 4.453	85.41 Femtoliters Standard Deviation 4.401

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Baseline; n=20, 19, 21	29.05 Picograms Standard Deviation 2.499	29.05 Picograms Standard Deviation 2.499	29.05 Picograms Standard Deviation 2.499
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 2; n=20, 19, 21	28.87 Picograms Standard Deviation 2.415	28.92 Picograms Standard Deviation 2.449	28.99 Picograms Standard Deviation 2.411
Absolute Values for Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 5; n=7, 5, 7	29.96 Picograms Standard Deviation 3.365	28.14 Picograms Standard Deviation 1.394	28.93 Picograms Standard Deviation 1.962

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 2; n=18, 18	-0.002 10^9 cells per liter Standard Deviation 0.0092	-0.002 10^9 cells per liter Standard Deviation 0.0092	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 5; n=9, 9	-0.002 10^9 cells per liter Standard Deviation 0.0083	-0.004 10^9 cells per liter Standard Deviation 0.0073	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 2; n=18, 18	0.016 10^9 cells per liter Standard Deviation 0.0322	0.022 10^9 cells per liter Standard Deviation 0.0387	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 5; n=9, 9	0.022 10^9 cells per liter Standard Deviation 0.0441	0.029 10^9 cells per liter Standard Deviation 0.0462	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 2; n=18, 18	0.109 10^9 cells per liter Standard Deviation 0.2237	0.127 10^9 cells per liter Standard Deviation 0.2350	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 5; n=9, 9	0.082 10^9 cells per liter Standard Deviation 0.2124	0.398 10^9 cells per liter Standard Deviation 0.3721	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 2; n=18, 18	0.006 10^9 cells per liter Standard Deviation 0.0581	0.008 10^9 cells per liter Standard Deviation 0.1164	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 5; n=9, 9	-0.009 10^9 cells per liter Standard Deviation 0.0821	-0.001 10^9 cells per liter Standard Deviation 0.0637	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 2; n=18, 18	-0.481 10^9 cells per liter Standard Deviation 0.7029	-0.683 10^9 cells per liter Standard Deviation 0.8597	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 5; n=9, 9	-0.291 10^9 cells per liter Standard Deviation 0.5628	0.549 10^9 cells per liter Standard Deviation 0.7398	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 2; n=18, 18	5.7 10^9 cells per liter Standard Deviation 21.18	9.0 10^9 cells per liter Standard Deviation 18.89	—
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 5; n=9, 9	20.8 10^9 cells per liter Standard Deviation 15.16	12.8 10^9 cells per liter Standard Deviation 22.55	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Erythrocytes Count-Part 1 Day 5; n=9, 9	0.253 10^12 cells per liter Standard Deviation 0.2320	0.214 10^12 cells per liter Standard Deviation 0.1729	—
Change From Baseline in Erythrocytes Count-Part 1 Day 2; n=18, 18	0.136 10^12 cells per liter Standard Deviation 0.2431	0.182 10^12 cells per liter Standard Deviation 0.2052	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Hemoglobin-Part 1 Day 2; n=18, 18	4.2 Grams per liter Standard Deviation 7.11	6.1 Grams per liter Standard Deviation 6.69	—
Change From Baseline in Hemoglobin-Part 1 Day 5; n=9, 9	8.7 Grams per liter Standard Deviation 7.66	7.6 Grams per liter Standard Deviation 6.04	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Hematocrit-Part 1 Day 5; n=9, 9	0.0189 Proportion of red blood cells in blood Standard Deviation 0.02196	0.0147 Proportion of red blood cells in blood Standard Deviation 0.01362	—
Change From Baseline in Hematocrit-Part 1 Day 2; n=18, 18	0.0094 Proportion of red blood cells in blood Standard Deviation 0.02265	0.0153 Proportion of red blood cells in blood Standard Deviation 0.01912	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 1 Day 2; n=18, 18	-0.59 Femtoliters Standard Deviation 0.984	-0.19 Femtoliters Standard Deviation 1.050	—
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 1 Day 5; n=9, 9	-0.84 Femtoliters Standard Deviation 0.911	-0.96 Femtoliters Standard Deviation 0.592	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 2; n=18, 18	0.01 Picograms Standard Deviation 0.344	0.14 Picograms Standard Deviation 0.365	—
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 1 Day 5; n=9, 9	0.26 Picograms Standard Deviation 0.343	0.20 Picograms Standard Deviation 0.439	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 5; n=7, 5, 7	0.007 10^9 cells per liter Standard Deviation 0.0423	-0.030 10^9 cells per liter Standard Deviation 0.0738	-0.009 10^9 cells per liter Standard Deviation 0.0402
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 2; n=20, 19, 21	-0.073 10^9 cells per liter Standard Deviation 0.2828	0.006 10^9 cells per liter Standard Deviation 0.3097	-0.068 10^9 cells per liter Standard Deviation 0.2313
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 2; n=20, 19, 21	-0.001 10^9 cells per liter Standard Deviation 0.0107	-0.003 10^9 cells per liter Standard Deviation 0.0129	0.001 10^9 cells per liter Standard Deviation 0.0128
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 5; n=7, 5, 7	0.000 10^9 cells per liter Standard Deviation 0.0100	0.006 10^9 cells per liter Standard Deviation 0.0114	0.000 10^9 cells per liter Standard Deviation 0.0129
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 2; n=20, 19, 21	0.001 10^9 cells per liter Standard Deviation 0.0424	-0.006 10^9 cells per liter Standard Deviation 0.0519	0.009 10^9 cells per liter Standard Deviation 0.0464
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 5; n=7, 5, 7	0.257 10^9 cells per liter Standard Deviation 0.2146	-0.010 10^9 cells per liter Standard Deviation 0.1454	-0.024 10^9 cells per liter Standard Deviation 0.4172
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 2; n=20, 19, 21	-0.028 10^9 cells per liter Standard Deviation 0.1055	-0.022 10^9 cells per liter Standard Deviation 0.0978	-0.022 10^9 cells per liter Standard Deviation 0.1272
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 5; n=7, 5, 7	0.024 10^9 cells per liter Standard Deviation 0.1081	0.000 10^9 cells per liter Standard Deviation 0.1058	0.034 10^9 cells per liter Standard Deviation 0.1509
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 2; n=20, 19, 21	-0.326 10^9 cells per liter Standard Deviation 0.7627	-0.336 10^9 cells per liter Standard Deviation 0.7377	-0.300 10^9 cells per liter Standard Deviation 0.7173
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 5; n=7, 5, 7	-0.216 10^9 cells per liter Standard Deviation 0.6986	0.154 10^9 cells per liter Standard Deviation 0.8131	0.134 10^9 cells per liter Standard Deviation 1.1111
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 2; n=20, 19, 21	21.6 10^9 cells per liter Standard Deviation 30.53	9.4 10^9 cells per liter Standard Deviation 25.64	21.4 10^9 cells per liter Standard Deviation 26.82
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 5; n=7, 5, 7	38.0 10^9 cells per liter Standard Deviation 26.03	-5.8 10^9 cells per liter Standard Deviation 28.08	-1.1 10^9 cells per liter Standard Deviation 30.28

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocytes count. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Erythrocytes Count-Part 2 Day 2; n=20, 19, 21	0.256 10^12 cells per liter Standard Deviation 0.1751	0.247 10^12 cells per liter Standard Deviation 0.2564	0.237 10^12 cells per liter Standard Deviation 0.1682
Change From Baseline in Erythrocytes Count-Part 2 Day 5; n=7, 5, 7	0.231 10^12 cells per liter Standard Deviation 0.1520	0.172 10^12 cells per liter Standard Deviation 0.1678	0.077 10^12 cells per liter Standard Deviation 0.2276

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Hemoglobin-Part 2 Day 2; n=20, 19, 21	6.5 Grams per liter Standard Deviation 4.96	6.3 Grams per liter Standard Deviation 7.39	6.0 Grams per liter Standard Deviation 4.21
Change From Baseline in Hemoglobin-Part 2 Day 5; n=7, 5, 7	7.0 Grams per liter Standard Deviation 3.11	4.2 Grams per liter Standard Deviation 5.50	2.4 Grams per liter Standard Deviation 5.32

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: hematocrit. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Hematocrit-Part 2 Day 5; n=7, 5, 7	0.0179 Proportion of red blood cells in blood Standard Deviation 0.01378	0.0106 Proportion of red blood cells in blood Standard Deviation 0.01731	0.0046 Proportion of red blood cells in blood Standard Deviation 0.01855
Change From Baseline in Hematocrit-Part 2 Day 2; n=20, 19, 21	0.0187 Proportion of red blood cells in blood Standard Deviation 0.01477	0.0182 Proportion of red blood cells in blood Standard Deviation 0.02179	0.0166 Proportion of red blood cells in blood Standard Deviation 0.01313

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular volume. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 2 Day 2; n=20, 19, 21	-0.35 Femtoliters Standard Deviation 0.841	-0.28 Femtoliters Standard Deviation 0.897	-0.41 Femtoliters Standard Deviation 0.774
Change From Baseline in Erythrocyte Mean Corpuscular Volume-Part 2 Day 5; n=7, 5, 7	-0.06 Femtoliters Standard Deviation 1.124	-0.02 Femtoliters Standard Deviation 1.103	-0.33 Femtoliters Standard Deviation 0.834

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following hematology parameter: erythrocyte mean corpuscular hemoglobin. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 2; n=20, 19, 21	-0.05 Picograms Standard Deviation 0.330	-0.05 Picograms Standard Deviation 0.276	-0.06 Picograms Standard Deviation 0.356
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin-Part 2 Day 5; n=7, 5, 7	0.10 Picograms Standard Deviation 0.365	0.18 Picograms Standard Deviation 0.536	0.13 Picograms Standard Deviation 0.553

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Baseline; n=18, 18	78.68 Micromoles per liter Standard Deviation 15.983	78.68 Micromoles per liter Standard Deviation 15.983	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 2; n=18, 18	80.87 Micromoles per liter Standard Deviation 15.104	80.11 Micromoles per liter Standard Deviation 14.243	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 5; n=9, 9	79.57 Micromoles per liter Standard Deviation 17.196	80.33 Micromoles per liter Standard Deviation 11.925	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Baseline; n=18, 18	10.56 Micromoles per liter Standard Deviation 3.578	10.56 Micromoles per liter Standard Deviation 3.578	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 2; n=18, 18	11.45 Micromoles per liter Standard Deviation 4.334	10.91 Micromoles per liter Standard Deviation 2.952	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 5; n=9, 9	11.49 Micromoles per liter Standard Deviation 1.590	11.41 Micromoles per liter Standard Deviation 3.867	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Baseline; n=18, 18	1.96 Micromoles per liter Standard Deviation 0.624	1.96 Micromoles per liter Standard Deviation 0.624	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 2; n=18, 18	1.91 Micromoles per liter Standard Deviation 0.643	1.86 Micromoles per liter Standard Deviation 0.631	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 5; n=9, 9	1.86 Micromoles per liter Standard Deviation 0.332	1.90 Micromoles per liter Standard Deviation 0.752	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Baseline; n=18, 18	306.7 Micromoles per liter Standard Deviation 87.16	306.7 Micromoles per liter Standard Deviation 87.16	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 2; n=18, 18	283.2 Micromoles per liter Standard Deviation 78.74	282.5 Micromoles per liter Standard Deviation 68.93	—
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 5; n=9, 9	281.4 Micromoles per liter Standard Deviation 75.17	282.9 Micromoles per liter Standard Deviation 67.35	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Baseline; n=18, 18	43.7 Grams per liter Standard Deviation 2.52	43.7 Grams per liter Standard Deviation 2.52	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 2; n=18, 18	43.8 Grams per liter Standard Deviation 2.53	44.4 Grams per liter Standard Deviation 2.96	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 5; n=9, 9	45.1 Grams per liter Standard Deviation 2.85	44.2 Grams per liter Standard Deviation 2.82	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Baseline; n=18, 18	27.5 Grams per liter Standard Deviation 3.84	27.5 Grams per liter Standard Deviation 3.84	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 2; n=18, 18	26.9 Grams per liter Standard Deviation 4.58	27.8 Grams per liter Standard Deviation 4.35	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 5; n=9, 9	26.2 Grams per liter Standard Deviation 4.58	28.0 Grams per liter Standard Deviation 4.97	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Baseline; n=18, 18	71.2 Grams per liter Standard Deviation 3.19	71.2 Grams per liter Standard Deviation 3.19	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 2; n=18, 18	70.7 Grams per liter Standard Deviation 5.07	72.2 Grams per liter Standard Deviation 5.43	—
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 5; n=9, 9	71.3 Grams per liter Standard Deviation 6.42	72.2 Grams per liter Standard Deviation 4.74	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 5; n=9, 9	44.3 Units per liter Standard Deviation 15.86	47.6 Units per liter Standard Deviation 22.94	—
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Baseline; n=18, 18	43.3 Units per liter Standard Deviation 14.96	43.3 Units per liter Standard Deviation 14.96	—
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 2; n=18, 18	46.7 Units per liter Standard Deviation 18.11	47.7 Units per liter Standard Deviation 21.31	—
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Baseline; n=18, 18	24.0 Units per liter Standard Deviation 11.24	24.0 Units per liter Standard Deviation 11.24	—
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 2; n=18, 18	26.7 Units per liter Standard Deviation 14.32	26.2 Units per liter Standard Deviation 14.26	—
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 5; n=9, 9	28.9 Units per liter Standard Deviation 14.98	24.7 Units per liter Standard Deviation 12.66	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 2; n=20, 19, 21	81.95 Micromoles per liter Standard Deviation 14.968	83.34 Micromoles per liter Standard Deviation 11.078	80.18 Micromoles per liter Standard Deviation 13.533
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 5; n=7, 5, 7	91.69 Micromoles per liter Standard Deviation 7.992	76.04 Micromoles per liter Standard Deviation 14.435	83.71 Micromoles per liter Standard Deviation 15.520
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Baseline; n=20, 19, 21	9.05 Micromoles per liter Standard Deviation 3.070	9.05 Micromoles per liter Standard Deviation 3.070	9.05 Micromoles per liter Standard Deviation 3.070
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Baseline; n=20, 19, 21	1.89 Micromoles per liter Standard Deviation 0.660	1.89 Micromoles per liter Standard Deviation 0.660	1.89 Micromoles per liter Standard Deviation 0.660
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Baseline; n=20, 19, 21	74.00 Micromoles per liter Standard Deviation 13.855	74.00 Micromoles per liter Standard Deviation 13.855	74.00 Micromoles per liter Standard Deviation 13.855
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 2; n=20, 19, 21	11.49 Micromoles per liter Standard Deviation 4.185	11.88 Micromoles per liter Standard Deviation 4.544	11.11 Micromoles per liter Standard Deviation 3.517
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 5; n=7, 5, 7	13.34 Micromoles per liter Standard Deviation 4.999	14.30 Micromoles per liter Standard Deviation 7.174	10.46 Micromoles per liter Standard Deviation 1.397
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 2; n=20, 19, 21	2.12 Micromoles per liter Standard Deviation 0.747	2.17 Micromoles per liter Standard Deviation 0.732	2.07 Micromoles per liter Standard Deviation 0.656
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 5; n=7, 5, 7	2.29 Micromoles per liter Standard Deviation 0.760	2.38 Micromoles per liter Standard Deviation 0.996	1.87 Micromoles per liter Standard Deviation 0.431
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Baseline; n=20, 19, 21	289.2 Micromoles per liter Standard Deviation 73.13	289.2 Micromoles per liter Standard Deviation 73.13	289.2 Micromoles per liter Standard Deviation 73.13
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 2; n=20, 19, 21	277.7 Micromoles per liter Standard Deviation 72.39	299.4 Micromoles per liter Standard Deviation 68.62	275.4 Micromoles per liter Standard Deviation 77.75
Absolute Values for Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 5; n=7, 5, 7	286.3 Micromoles per liter Standard Deviation 48.83	291.2 Micromoles per liter Standard Deviation 96.66	313.6 Micromoles per liter Standard Deviation 79.74

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Baseline; n=20, 19, 21	43.8 Grams per liter Standard Deviation 2.90	43.8 Grams per liter Standard Deviation 2.90	43.8 Grams per liter Standard Deviation 2.90
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 2; n=20, 19, 21	45.6 Grams per liter Standard Deviation 2.68	45.4 Grams per liter Standard Deviation 2.27	45.7 Grams per liter Standard Deviation 2.99
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 5; n=7, 5, 7	48.0 Grams per liter Standard Deviation 2.58	43.4 Grams per liter Standard Deviation 2.07	45.1 Grams per liter Standard Deviation 2.97
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Baseline; n=20, 19, 21	26.5 Grams per liter Standard Deviation 3.19	26.5 Grams per liter Standard Deviation 3.19	26.5 Grams per liter Standard Deviation 3.19
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 2; n=20, 19, 21	26.6 Grams per liter Standard Deviation 3.33	26.0 Grams per liter Standard Deviation 3.43	26.4 Grams per liter Standard Deviation 3.43
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 5; n=7, 5, 7	23.6 Grams per liter Standard Deviation 1.51	28.2 Grams per liter Standard Deviation 2.49	26.7 Grams per liter Standard Deviation 1.25
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Baseline; n=20, 19, 21	70.3 Grams per liter Standard Deviation 4.23	70.3 Grams per liter Standard Deviation 4.23	70.3 Grams per liter Standard Deviation 4.23
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 2; n=20, 19, 21	72.2 Grams per liter Standard Deviation 3.56	71.4 Grams per liter Standard Deviation 3.20	72.1 Grams per liter Standard Deviation 4.31
Absolute Values for Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 5; n=7, 5, 7	71.6 Grams per liter Standard Deviation 3.15	71.6 Grams per liter Standard Deviation 2.07	71.9 Grams per liter Standard Deviation 2.85

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 5; n=7, 5, 7	21.9 Units per liter Standard Deviation 9.39	17.6 Units per liter Standard Deviation 8.23	24.1 Units per liter Standard Deviation 13.26
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Baseline; n=20, 19, 21	49.3 Units per liter Standard Deviation 16.33	49.3 Units per liter Standard Deviation 16.33	49.3 Units per liter Standard Deviation 16.33
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 2; n=20, 19, 21	48.3 Units per liter Standard Deviation 15.91	49.4 Units per liter Standard Deviation 18.86	50.1 Units per liter Standard Deviation 18.22
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 5; n=7, 5, 7	49.6 Units per liter Standard Deviation 22.33	48.8 Units per liter Standard Deviation 8.53	43.6 Units per liter Standard Deviation 14.89
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Baseline; n=20, 19, 21	23.8 Units per liter Standard Deviation 17.88	23.8 Units per liter Standard Deviation 17.88	23.8 Units per liter Standard Deviation 17.88
Absolute Values for Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 2; n=20, 19, 21	20.4 Units per liter Standard Deviation 10.04	22.2 Units per liter Standard Deviation 12.81	24.1 Units per liter Standard Deviation 11.45

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 2; n=18, 18	2.19 Micromoles per liter Standard Deviation 4.721	1.43 Micromoles per liter Standard Deviation 6.188	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Creatinine; Day 5; n=9, 9	3.64 Micromoles per liter Standard Deviation 3.780	-1.10 Micromoles per liter Standard Deviation 5.169	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 2; n=18, 18	0.89 Micromoles per liter Standard Deviation 2.659	0.36 Micromoles per liter Standard Deviation 2.632	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Total bilirubin; Day 5; n=9, 9	0.59 Micromoles per liter Standard Deviation 3.297	1.20 Micromoles per liter Standard Deviation 2.513	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 2; n=18, 18	-0.05 Micromoles per liter Standard Deviation 0.399	-0.10 Micromoles per liter Standard Deviation 0.387	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Direct bilirubin; Day 5; n=9, 9	-0.12 Micromoles per liter Standard Deviation 0.526	-0.04 Micromoles per liter Standard Deviation 0.361	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 2; n=18, 18	-23.5 Micromoles per liter Standard Deviation 46.62	-24.2 Micromoles per liter Standard Deviation 43.16	—
Change From Baseline Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 1 Urate; Day 5; n=9, 9	-29.8 Micromoles per liter Standard Deviation 46.45	-19.3 Micromoles per liter Standard Deviation 36.96	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALT; Day 2; n=18, 18	-0.2 International units per liter Standard Deviation 5.34	-3.6 International units per liter Standard Deviation 8.39	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALT; Day 5; n=9, 9	1.3 International units per liter Standard Deviation 7.87	-5.3 International units per liter Standard Deviation 12.32	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALP; Day 2; n=18, 18	-2.4 International units per liter Standard Deviation 5.25	-2.5 International units per liter Standard Deviation 4.74	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 ALP; Day 5; n=9, 9	-1.7 International units per liter Standard Deviation 7.40	-1.9 International units per liter Standard Deviation 3.37	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 AST; Day 2; n=18, 18	-2.6 International units per liter Standard Deviation 4.68	-4.2 International units per liter Standard Deviation 6.57	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 AST; Day 5; n=9, 9	-1.4 International units per liter Standard Deviation 3.84	-6.0 International units per liter Standard Deviation 8.70	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 GGT; Day 2; n=18, 18	-1.2 International units per liter Standard Deviation 1.93	-0.4 International units per liter Standard Deviation 2.94	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 GGT; Day 5; n=9, 9	-2.1 International units per liter Standard Deviation 2.47	-1.6 International units per liter Standard Deviation 3.88	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 CK; Day 2; n=18, 18	-39.6 International units per liter Standard Deviation 39.29	-34.8 International units per liter Standard Deviation 53.99	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 CK; Day 5; n=9, 9	-23.3 International units per liter Standard Deviation 28.33	-46.2 International units per liter Standard Deviation 76.08	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 LDH; Day 2; n=18, 18	-18.7 International units per liter Standard Deviation 11.00	-16.0 International units per liter Standard Deviation 11.86	—
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 1 LDH; Day 5; n=9, 9	-13.9 International units per liter Standard Deviation 16.12	-13.4 International units per liter Standard Deviation 16.13	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 2; n=18, 18	0.1 Grams per liter Standard Deviation 2.80	0.7 Grams per liter Standard Deviation 3.04	—
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Albumin; Day 5; n=9, 9	0.9 Grams per liter Standard Deviation 3.37	1.0 Grams per liter Standard Deviation 3.00	—
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 2; n=18, 18	-0.6 Grams per liter Standard Deviation 2.50	0.3 Grams per liter Standard Deviation 2.37	—
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Globulin; Day 5; n=9, 9	-0.7 Grams per liter Standard Deviation 2.78	-0.1 Grams per liter Standard Deviation 1.76	—
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 2; n=18, 18	-0.5 Grams per liter Standard Deviation 4.82	1.0 Grams per liter Standard Deviation 4.79	—
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 1 Protein; Day 5; n=9, 9	0.2 Grams per liter Standard Deviation 5.93	0.9 Grams per liter Standard Deviation 4.54	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 2; n=18, 18	3.3 Units per liter Standard Deviation 5.66	4.3 Units per liter Standard Deviation 8.75	—
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Amylase; Day 5; n=9, 9	1.0 Units per liter Standard Deviation 6.52	4.2 Units per liter Standard Deviation 6.22	—
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 2; n=18, 18	2.7 Units per liter Standard Deviation 8.27	2.2 Units per liter Standard Deviation 5.15	—
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 1 Lipase; Day 5; n=9, 9	4.0 Units per liter Standard Deviation 6.56	1.6 Units per liter Standard Deviation 3.28	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: creatinine, total bilirubin, direct bilirubin and urate. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 2; n=20, 19, 21	7.25 Micromoles per liter Standard Deviation 5.306	7.41 Micromoles per liter Standard Deviation 4.836	6.18 Micromoles per liter Standard Deviation 4.833
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Creatinine; Day 5; n=7, 5, 7	10.10 Micromoles per liter Standard Deviation 5.536	8.86 Micromoles per liter Standard Deviation 4.565	7.19 Micromoles per liter Standard Deviation 5.827
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 2; n=20, 19, 21	2.29 Micromoles per liter Standard Deviation 2.650	2.47 Micromoles per liter Standard Deviation 3.448	2.06 Micromoles per liter Standard Deviation 2.729
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Total bilirubin; Day 5; n=7, 5, 7	3.89 Micromoles per liter Standard Deviation 3.133	4.04 Micromoles per liter Standard Deviation 4.689	1.69 Micromoles per liter Standard Deviation 1.791
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 2; n=20, 19, 21	0.21 Micromoles per liter Standard Deviation 0.524	0.22 Micromoles per liter Standard Deviation 0.550	0.18 Micromoles per liter Standard Deviation 0.494
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Direct bilirubin; Day 5; n=7, 5, 7	0.31 Micromoles per liter Standard Deviation 0.495	0.16 Micromoles per liter Standard Deviation 0.611	0.11 Micromoles per liter Standard Deviation 0.389
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 2; n=20, 19, 21	-16.5 Micromoles per liter Standard Deviation 31.57	-0.5 Micromoles per liter Standard Deviation 29.49	-13.8 Micromoles per liter Standard Deviation 32.92
Change From Baseline in Chemistry Parameters: Creatinine, Total Bilirubin, Direct Bilirubin and Urate-Part 2 Urate; Day 5; n=7, 5, 7	-6.7 Micromoles per liter Standard Deviation 29.86	-4.0 Micromoles per liter Standard Deviation 34.62	3.3 Micromoles per liter Standard Deviation 27.67

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: calcium, glucose, potassium, sodium, chloride, phosphate, BUN, triglycerides, cholesterol, anion gap and carbon dioxide. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: ALT, ALP, AST, GGT, CK and LDH. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 5; n=7, 5, 7	-17.3 International units per liter Standard Deviation 14.95	-17.8 International units per liter Standard Deviation 3.27	-10.4 International units per liter Standard Deviation 15.05
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 2; n=20, 19, 21	-4.9 International units per liter Standard Deviation 8.61	-2.5 International units per liter Standard Deviation 4.06	-2.2 International units per liter Standard Deviation 8.48
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 5; n=7, 5, 7	-9.7 International units per liter Standard Deviation 13.03	-3.4 International units per liter Standard Deviation 4.39	5.7 International units per liter Standard Deviation 9.23
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 2; n=20, 19, 21	6.1 International units per liter Standard Deviation 5.61	5.9 International units per liter Standard Deviation 5.91	6.3 International units per liter Standard Deviation 6.21
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 5; n=7, 5, 7	3.9 International units per liter Standard Deviation 6.69	2.2 International units per liter Standard Deviation 6.22	-0.4 International units per liter Standard Deviation 6.50
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 2; n=20, 19, 21	-3.3 International units per liter Standard Deviation 5.18	-2.6 International units per liter Standard Deviation 4.40	-2.0 International units per liter Standard Deviation 4.88
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 5; n=7, 5, 7	-5.1 International units per liter Standard Deviation 6.26	-2.8 International units per liter Standard Deviation 4.66	0.6 International units per liter Standard Deviation 3.36
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 2; n=20, 19, 21	-1.1 International units per liter Standard Deviation 2.65	-0.4 International units per liter Standard Deviation 1.80	0.2 International units per liter Standard Deviation 3.09
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 5; n=7, 5, 7	-2.4 International units per liter Standard Deviation 3.31	-1.4 International units per liter Standard Deviation 2.70	2.1 International units per liter Standard Deviation 5.73
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 2; n=20, 19, 21	-15.4 International units per liter Standard Deviation 27.15	-10.7 International units per liter Standard Deviation 40.57	-12.6 International units per liter Standard Deviation 31.50
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 5; n=7, 5, 7	1.1 International units per liter Standard Deviation 78.79	9.4 International units per liter Standard Deviation 92.62	29.9 International units per liter Standard Deviation 152.85
Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 2; n=20, 19, 21	-12.2 International units per liter Standard Deviation 10.28	-12.4 International units per liter Standard Deviation 12.05	-11.5 International units per liter Standard Deviation 11.97

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: albumin, globulin and protein. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 5; n=7, 5, 7	3.4 Grams per liter Standard Deviation 1.40	1.8 Grams per liter Standard Deviation 0.84	1.1 Grams per liter Standard Deviation 1.46
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Albumin; Day 2; n=20, 19, 21	2.0 Grams per liter Standard Deviation 1.85	1.8 Grams per liter Standard Deviation 2.57	1.9 Grams per liter Standard Deviation 1.95
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 2; n=20, 19, 21	0.2 Grams per liter Standard Deviation 1.79	-0.1 Grams per liter Standard Deviation 2.26	-0.1 Grams per liter Standard Deviation 1.76
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Globulin; Day 5; n=7, 5, 7	0.1 Grams per liter Standard Deviation 1.86	0.1 Grams per liter Standard Deviation 3.39	-1.3 Grams per liter Standard Deviation 1.80
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 2; n=20, 19, 21	2.1 Grams per liter Standard Deviation 3.01	1.7 Grams per liter Standard Deviation 4.28	1.8 Grams per liter Standard Deviation 3.01
Change From Baseline in Chemistry Parameters: Albumin, Globulin and Protein-Part 2 Protein; Day 5; n=7, 5, 7	3.6 Grams per liter Standard Deviation 2.23	2.8 Grams per liter Standard Deviation 4.09	-0.1 Grams per liter Standard Deviation 3.02

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Blood samples were collected for the assessment of following clinical chemistry parameters: amylase and lipase. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 2; n=20, 19, 21	0.7 Units per liter Standard Deviation 5.68	1.8 Units per liter Standard Deviation 8.70	0.8 Units per liter Standard Deviation 8.27
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Amylase; Day 5; n=7, 5, 7	4.4 Units per liter Standard Deviation 4.86	-1.8 Units per liter Standard Deviation 10.16	-4.4 Units per liter Standard Deviation 8.26
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 2; n=20, 19, 21	-2.6 Units per liter Standard Deviation 15.99	-1.4 Units per liter Standard Deviation 13.01	0.3 Units per liter Standard Deviation 17.39
Change From Baseline in Chemistry Parameters: Amylase and Lipase-Part 2 Lipase; Day 5; n=7, 5, 7	6.3 Units per liter Standard Deviation 7.54	-3.0 Units per liter Standard Deviation 14.27	-9.6 Units per liter Standard Deviation 24.84

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Urine Parameter: Specific Gravity-Part 1 Day 2; n=18, 18	1.0152 Ratio Standard Deviation 0.00685	1.0158 Ratio Standard Deviation 0.00584	—
Absolute Values for Urine Parameter: Specific Gravity-Part 1 Baseline; n=18, 18	1.0120 Ratio Standard Deviation 0.00915	1.0120 Ratio Standard Deviation 0.00915	—
Absolute Values for Urine Parameter: Specific Gravity-Part 1 Day 5; n=9, 9	1.0201 Ratio Standard Deviation 0.00664	1.0161 Ratio Standard Deviation 0.00434	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Urine Parameter: Urobilinogen-Part 1 Baseline; n=18, 18	4.1384 Micromoles per liter Standard Deviation 3.19235	4.1384 Micromoles per liter Standard Deviation 3.19235	—
Absolute Values for Urine Parameter: Urobilinogen-Part 1 Day 2; n=18, 18	3.3860 Micromoles per liter Standard Deviation 0.00000	4.1384 Micromoles per liter Standard Deviation 3.19235	—
Absolute Values for Urine Parameter: Urobilinogen-Part 1 Day 5; n=9, 9	3.3860 Micromoles per liter Standard Deviation 0.00000	3.3860 Micromoles per liter Standard Deviation 0.00000	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Urine Parameter: Potential of Hydrogen (pH)-Part 1 Day 2; n=18, 18	6.14 pH Standard Deviation 0.682	6.25 pH Standard Deviation 0.600	—
Absolute Values for Urine Parameter: Potential of Hydrogen (pH)-Part 1 Baseline; n=18, 18	6.03 pH Standard Deviation 0.696	6.03 pH Standard Deviation 0.696	—
Absolute Values for Urine Parameter: Potential of Hydrogen (pH)-Part 1 Day 5; n=9, 9	5.72 pH Standard Deviation 0.441	5.89 pH Standard Deviation 0.697	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Urine Parameter: Specific Gravity-Part 2 Baseline; n=20, 19, 21	1.0080 Ratio Standard Deviation 0.00735	1.0080 Ratio Standard Deviation 0.00735	1.0080 Ratio Standard Deviation 0.00735
Absolute Values for Urine Parameter: Specific Gravity-Part 2 Day 5; n=7, 5, 7	1.0180 Ratio Standard Deviation 0.00632	1.0248 Ratio Standard Deviation 0.00526	1.0171 Ratio Standard Deviation 0.00999
Absolute Values for Urine Parameter: Specific Gravity-Part 2 Day 2; n=20, 19, 21	1.0166 Ratio Standard Deviation 0.00675	1.0151 Ratio Standard Deviation 0.00552	1.0163 Ratio Standard Deviation 0.00419

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Urine Parameter: Urobilinogen-Part 2 Day 5; n=7, 5, 7	3.3860 Micromoles per liter Standard Deviation 0.00000	6.0948 Micromoles per liter Standard Deviation 6.05706	5.3209 Micromoles per liter Standard Deviation 5.11915
Absolute Values for Urine Parameter: Urobilinogen-Part 2 Baseline; n=20, 19, 21	4.6759 Micromoles per liter Standard Deviation 4.03794	4.6759 Micromoles per liter Standard Deviation 4.03794	4.6759 Micromoles per liter Standard Deviation 4.03794
Absolute Values for Urine Parameter: Urobilinogen-Part 2 Day 2; n=20, 19, 21	4.0632 Micromoles per liter Standard Deviation 3.02853	3.3860 Micromoles per liter Standard Deviation 0.00000	3.3860 Micromoles per liter Standard Deviation 0.00000

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Urine Parameter: pH-Part 2 Baseline; n=20, 19, 21	6.36 pH Standard Deviation 0.727	6.36 pH Standard Deviation 0.727	6.36 pH Standard Deviation 0.727
Absolute Values for Urine Parameter: pH-Part 2 Day 2; n=20, 19, 21	6.15 pH Standard Deviation 0.690	6.08 pH Standard Deviation 0.584	6.10 pH Standard Deviation 0.718
Absolute Values for Urine Parameter: pH-Part 2 Day 5; n=7, 5, 7	5.86 pH Standard Deviation 0.627	5.60 pH Standard Deviation 0.418	6.21 pH Standard Deviation 0.393

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Urine Parameter: Specific Gravity-Part 1 Day 5; n=9, 9	0.0088 Ratio Standard Deviation 0.01210	0.0034 Ratio Standard Deviation 0.01180	—
Change From Baseline in Urine Parameter: Specific Gravity-Part 1 Day 2; n=18, 18	0.0032 Ratio Standard Deviation 0.01242	0.0038 Ratio Standard Deviation 0.01043	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Urine Parameter: Urobilinogen-Part 1 Day 2; n=18, 18	-0.7524 Micromoles per liter Standard Deviation 3.19235	0.0000 Micromoles per liter Standard Deviation 4.64555	—
Change From Baseline in Urine Parameter: Urobilinogen-Part 1 Day 5; n=9, 9	0.0000 Micromoles per liter Standard Deviation 0.00000	-1.5049 Micromoles per liter Standard Deviation 4.51467	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Urine Parameter: pH-Part 1 Day 2; n=18, 18	0.11 pH Standard Deviation 1.008	0.22 pH Standard Deviation 0.974	—
Change From Baseline in Urine Parameter: pH-Part 1 Day 5; n=9, 9	-0.17 pH Standard Deviation 0.559	-0.28 pH Standard Deviation 1.121	—

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine, indicated as ratio of urine density to water density. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Urine Parameter: Specific Gravity-Part 2 Day 2; n=20, 19, 21	0.0084 Ratio Standard Deviation 0.00942	0.0066 Ratio Standard Deviation 0.00718	0.0083 Ratio Standard Deviation 0.00728
Change From Baseline in Urine Parameter: Specific Gravity-Part 2 Day 5; n=7, 5, 7	0.0109 Ratio Standard Deviation 0.00825	0.0140 Ratio Standard Deviation 0.01142	0.0091 Ratio Standard Deviation 0.00956

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Urine Parameter: Urobilinogen-Part 2 Day 2; n=20, 19, 21	-0.6772 Micromoles per liter Standard Deviation 5.33680	-1.4275 Micromoles per liter Standard Deviation 4.27045	-1.2899 Micromoles per liter Standard Deviation 4.07394
Change From Baseline in Urine Parameter: Urobilinogen-Part 2 Day 5; n=7, 5, 7	0.0000 Micromoles per liter Standard Deviation 0.00000	-2.7088 Micromoles per liter Standard Deviation 6.05706	1.9349 Micromoles per liter Standard Deviation 5.11915

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 2 and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Urine samples were collected at indicated time points for the assessment of urine pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first dose of study drug administration. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Urine Parameter: pH-Part 2 Day 5; n=7, 5, 7	-0.43 pH Standard Deviation 0.787	-0.80 pH Standard Deviation 0.837	0.07 pH Standard Deviation 0.450
Change From Baseline in Urine Parameter: pH-Part 2 Day 2; n=20, 19, 21	-0.18 pH Standard Deviation 0.799	-0.18 pH Standard Deviation 0.730	-0.26 pH Standard Deviation 0.664

SECONDARY outcome

Timeframe: Day 2 and Day 5

Population: Safety Population

Urine samples were collected at indicated time points for the assessment of following urine parameters: bilirubin, glucose, ketones, nitrite, leukocyte esterase, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner, and results can be read as Trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Only parameters and time points with abnormal results have been presented.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 2, Trace	0 Participants	1 Participants	—
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 2, 1+	1 Participants	0 Participants	—
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 5, Trace	0 Participants	1 Participants	—
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Leukocyte esterase, Day 5, 1+	0 Participants	1 Participants	—
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Occult blood, Day 2, Trace	1 Participants	1 Participants	—
Number of Participants With Abnormal Urine Dipstick Results-Part 1 Occult blood, Day 2, 1+	1 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Day 2 and Day 5

Population: Safety Population

Urine samples were collected at indicated time points for the assessment of following urine parameters: bilirubin, glucose, ketones, nitrite, leukocyte esterase, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner, and results can be read as Trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Only parameters and time points with abnormal results have been presented.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Ketones; Day 5; Trace	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Ketones; Day 5; 2+	0 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Leukocyte esterase; Day 2; 1+	0 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Occult blood; Day 2; Trace	0 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Occult blood; Day 2; 2+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urine Dipstick Results-Part 2 Occult blood; Day 2; 3+	0 Participants	0 Participants	2 Participants

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Day 1 (2 hours); n=18, 18	383.3 Milliseconds Standard Deviation 13.71	383.6 Milliseconds Standard Deviation 24.11	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Baseline; n=18, 18	164.1 Milliseconds Standard Deviation 22.81	162.3 Milliseconds Standard Deviation 20.76	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Day 1 (2 hours); n=18, 18	166.3 Milliseconds Standard Deviation 21.55	158.7 Milliseconds Standard Deviation 19.95	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Day 1 (4 hours); n=18, 18	160.6 Milliseconds Standard Deviation 20.94	158.9 Milliseconds Standard Deviation 19.19	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 PR interval, Day 5; n=9, 9	161.8 Milliseconds Standard Deviation 11.68	169.3 Milliseconds Standard Deviation 26.14	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Baseline; n=18, 18	93.4 Milliseconds Standard Deviation 9.30	92.5 Milliseconds Standard Deviation 8.09	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Day 1 (2 hours); n=18, 18	91.9 Milliseconds Standard Deviation 8.76	92.6 Milliseconds Standard Deviation 9.00	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Day 1 (4 hours); n=18, 18	94.1 Milliseconds Standard Deviation 8.88	93.8 Milliseconds Standard Deviation 9.90	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QRS duration, Day 5; n=9, 9	94.3 Milliseconds Standard Deviation 11.65	92.4 Milliseconds Standard Deviation 8.25	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Baseline; n=18, 18	395.1 Milliseconds Standard Deviation 14.22	394.4 Milliseconds Standard Deviation 24.04	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Day 1 (4 hours); n=18, 18	404.8 Milliseconds Standard Deviation 16.36	402.0 Milliseconds Standard Deviation 27.67	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QT interval, Day 5; n=9, 9	393.4 Milliseconds Standard Deviation 16.38	402.7 Milliseconds Standard Deviation 18.71	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Baseline; n=18, 18	399.4 Milliseconds Standard Deviation 9.76	401.9 Milliseconds Standard Deviation 15.01	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Day 1 (2 hours); n=18, 18	389.5 Milliseconds Standard Deviation 12.11	392.8 Milliseconds Standard Deviation 15.09	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Day 1 (4 hours); n=18, 18	398.7 Milliseconds Standard Deviation 11.13	402.6 Milliseconds Standard Deviation 19.46	—
Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF)-Part 1 QTcF interval, Day 5; n=9, 9	400.8 Milliseconds Standard Deviation 13.34	399.4 Milliseconds Standard Deviation 11.98	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Baseline; n=20, 19, 21	166.4 Milliseconds Standard Deviation 16.48	166.2 Milliseconds Standard Deviation 15.40	166.8 Milliseconds Standard Deviation 17.01
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (2 hours); n=20, 19, 21	163.9 Milliseconds Standard Deviation 18.45	166.8 Milliseconds Standard Deviation 15.23	161.7 Milliseconds Standard Deviation 16.82
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (4 hours); n=20, 19, 21	165.2 Milliseconds Standard Deviation 17.74	165.7 Milliseconds Standard Deviation 15.29	162.6 Milliseconds Standard Deviation 13.99
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 5; n=7, 5, 7	173.4 Milliseconds Standard Deviation 19.16	171.6 Milliseconds Standard Deviation 14.57	163.1 Milliseconds Standard Deviation 12.36
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Baseline; n=20, 19, 21	92.1 Milliseconds Standard Deviation 9.76	91.7 Milliseconds Standard Deviation 9.02	90.1 Milliseconds Standard Deviation 10.42
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (2 hours); n=20, 19, 21	88.9 Milliseconds Standard Deviation 9.68	92.6 Milliseconds Standard Deviation 9.82	89.7 Milliseconds Standard Deviation 9.86
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (4 hours); n=20, 19, 21	91.1 Milliseconds Standard Deviation 10.63	93.2 Milliseconds Standard Deviation 8.45	90.3 Milliseconds Standard Deviation 8.69
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 5; n=7, 5, 7	101.1 Milliseconds Standard Deviation 7.10	85.8 Milliseconds Standard Deviation 8.07	88.7 Milliseconds Standard Deviation 5.28
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Baseline; n=20, 19, 21	391.8 Milliseconds Standard Deviation 28.22	388.5 Milliseconds Standard Deviation 24.78	389.7 Milliseconds Standard Deviation 26.09
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (2 hours); n=20, 19, 21	379.7 Milliseconds Standard Deviation 25.70	399.2 Milliseconds Standard Deviation 22.43	376.2 Milliseconds Standard Deviation 22.54
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (4 hours); n=20, 19, 21	401.0 Milliseconds Standard Deviation 25.84	406.9 Milliseconds Standard Deviation 22.25	389.1 Milliseconds Standard Deviation 25.95
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 5; n=7, 5, 7	401.7 Milliseconds Standard Deviation 33.29	391.0 Milliseconds Standard Deviation 10.27	378.9 Milliseconds Standard Deviation 25.15
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Baseline; n=20, 19, 21	395.3 Milliseconds Standard Deviation 21.06	392.4 Milliseconds Standard Deviation 19.45	391.9 Milliseconds Standard Deviation 21.63
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (2 hours); n=20, 19, 21	384.0 Milliseconds Standard Deviation 19.91	391.7 Milliseconds Standard Deviation 21.77	388.3 Milliseconds Standard Deviation 18.91
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (4 hours); n=20, 19, 21	396.8 Milliseconds Standard Deviation 21.90	395.5 Milliseconds Standard Deviation 20.75	393.3 Milliseconds Standard Deviation 20.78
Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 5; n=7, 5, 7	391.9 Milliseconds Standard Deviation 30.45	402.4 Milliseconds Standard Deviation 7.70	388.1 Milliseconds Standard Deviation 22.81

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QRS duration, Day 5; n=9, 9	-0.3 Milliseconds Standard Deviation 3.74	0.8 Milliseconds Standard Deviation 3.46	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QT interval, Day 1 (2 hours); n=18, 18	-11.8 Milliseconds Standard Deviation 10.70	-10.8 Milliseconds Standard Deviation 11.18	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QT interval, Day 1 (4 hours); n=18, 18	9.7 Milliseconds Standard Deviation 13.99	7.6 Milliseconds Standard Deviation 16.85	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QT interval, Day 5; n=9, 9	-1.3 Milliseconds Standard Deviation 10.00	5.0 Milliseconds Standard Deviation 26.51	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QTcF interval, Day 1 (2 hours); n=18, 18	-9.9 Milliseconds Standard Deviation 6.49	-9.1 Milliseconds Standard Deviation 9.16	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QTcF interval, Day 1 (4 hours); n=18, 18	-0.7 Milliseconds Standard Deviation 7.71	0.7 Milliseconds Standard Deviation 9.23	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QTcF interval, Day 5; n=9, 9	-0.7 Milliseconds Standard Deviation 7.19	3.9 Milliseconds Standard Deviation 7.93	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 PR interval, Day 1 (2 hours); n=18, 18	2.2 Milliseconds Standard Deviation 8.35	-3.6 Milliseconds Standard Deviation 10.01	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 PR interval, Day 1 (4 hours); n=18, 18	-3.6 Milliseconds Standard Deviation 11.61	-3.3 Milliseconds Standard Deviation 10.85	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 PR interval, Day 5; n=9, 9	-0.9 Milliseconds Standard Deviation 13.72	3.2 Milliseconds Standard Deviation 8.35	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QRS duration, Day 1 (2 hours); n=18, 18	-1.5 Milliseconds Standard Deviation 2.81	0.1 Milliseconds Standard Deviation 6.06	—
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 1 QRS duration, Day 1 (4 hours); n=18, 18	0.7 Milliseconds Standard Deviation 3.63	1.3 Milliseconds Standard Deviation 4.92	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Day 1 (2 hours and 4 hours) and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. ECGs were obtained using an ECG machine that automatically measured PR, QRS, QT, and QTcF intervals. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (4 hours); n=20, 19, 21	-1.0 Milliseconds Standard Deviation 4.18	1.5 Milliseconds Standard Deviation 4.45	0.2 Milliseconds Standard Deviation 4.12
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (2 hours); n=20, 19, 21	-12.1 Milliseconds Standard Deviation 18.05	10.6 Milliseconds Standard Deviation 12.36	-13.4 Milliseconds Standard Deviation 15.31
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (2 hours); n=20, 19, 21	-11.3 Milliseconds Standard Deviation 7.04	-0.6 Milliseconds Standard Deviation 7.33	-3.5 Milliseconds Standard Deviation 8.70
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 5; n=7, 5, 7	-0.4 Milliseconds Standard Deviation 9.34	-1.4 Milliseconds Standard Deviation 3.91	1.7 Milliseconds Standard Deviation 8.30
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (2 hours); n=20, 19, 21	-2.5 Milliseconds Standard Deviation 7.02	0.7 Milliseconds Standard Deviation 7.90	-5.0 Milliseconds Standard Deviation 8.29
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 1 (4 hours); n=20, 19, 21	-1.2 Milliseconds Standard Deviation 8.47	-0.4 Milliseconds Standard Deviation 11.52	-4.2 Milliseconds Standard Deviation 6.79
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 PR interval, Day 5; n=7, 5, 7	2.0 Milliseconds Standard Deviation 4.08	1.6 Milliseconds Standard Deviation 11.26	-2.7 Milliseconds Standard Deviation 16.42
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 1 (2 hours); n=20, 19, 21	-3.2 Milliseconds Standard Deviation 3.44	0.9 Milliseconds Standard Deviation 3.90	-0.5 Milliseconds Standard Deviation 3.03
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QRS duration, Day 5; n=7, 5, 7	0.4 Milliseconds Standard Deviation 3.21	-0.4 Milliseconds Standard Deviation 3.13	0.4 Milliseconds Standard Deviation 2.88
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 1 (4 hours); n=20, 19, 21	9.2 Milliseconds Standard Deviation 18.08	18.4 Milliseconds Standard Deviation 12.90	-0.6 Milliseconds Standard Deviation 14.14
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QT interval, Day 5; n=7, 5, 7	-2.1 Milliseconds Standard Deviation 10.67	-12.4 Milliseconds Standard Deviation 13.28	-2.9 Milliseconds Standard Deviation 7.95
Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval-Part 2 QTcF interval, Day 1 (4 hours); n=20, 19, 21	1.6 Milliseconds Standard Deviation 7.50	3.1 Milliseconds Standard Deviation 7.75	1.4 Milliseconds Standard Deviation 7.64

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 2	113.8 Millimeters of mercury Standard Deviation 10.32	115.1 Millimeters of mercury Standard Deviation 11.94	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 3	113.6 Millimeters of mercury Standard Deviation 12.13	113.3 Millimeters of mercury Standard Deviation 9.71	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 4	112.2 Millimeters of mercury Standard Deviation 11.11	113.9 Millimeters of mercury Standard Deviation 10.57	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 2	70.1 Millimeters of mercury Standard Deviation 7.06	71.3 Millimeters of mercury Standard Deviation 10.56	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Baseline	118.3 Millimeters of mercury Standard Deviation 9.73	117.4 Millimeters of mercury Standard Deviation 12.26	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 SBP; Day 5	112.2 Millimeters of mercury Standard Deviation 9.62	113.8 Millimeters of mercury Standard Deviation 8.91	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Baseline	72.1 Millimeters of mercury Standard Deviation 8.35	73.4 Millimeters of mercury Standard Deviation 8.51	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 3	70.4 Millimeters of mercury Standard Deviation 7.72	69.1 Millimeters of mercury Standard Deviation 8.46	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 4	70.2 Millimeters of mercury Standard Deviation 6.98	68.7 Millimeters of mercury Standard Deviation 6.77	—
Absolute Values for Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)-Part 1 DBP; Day 5	70.1 Millimeters of mercury Standard Deviation 7.68	68.9 Millimeters of mercury Standard Deviation 5.76	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 5	64.4 Beats per minute Standard Deviation 6.97	66.9 Beats per minute Standard Deviation 8.39	—
Absolute Values for Vital Sign: Pulse Rate-Part 1 Baseline	65.7 Beats per minute Standard Deviation 5.27	66.2 Beats per minute Standard Deviation 10.00	—
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 2	66.7 Beats per minute Standard Deviation 7.02	68.4 Beats per minute Standard Deviation 8.71	—
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 3	67.4 Beats per minute Standard Deviation 7.79	68.6 Beats per minute Standard Deviation 9.58	—
Absolute Values for Vital Sign: Pulse Rate-Part 1 Day 4	67.4 Beats per minute Standard Deviation 7.89	65.6 Beats per minute Standard Deviation 9.37	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Baseline; n=18, 18	14.0 Breaths per minute Standard Deviation 2.66	14.9 Breaths per minute Standard Deviation 1.71	—
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 2; n=17, 17	13.1 Breaths per minute Standard Deviation 2.56	13.9 Breaths per minute Standard Deviation 2.69	—
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 3; n=17, 18	14.7 Breaths per minute Standard Deviation 2.11	15.2 Breaths per minute Standard Deviation 2.49	—
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 4; n=18, 18	13.9 Breaths per minute Standard Deviation 2.87	14.7 Breaths per minute Standard Deviation 3.07	—
Absolute Values for Vital Sign: Respiratory Rate-Part 1 Day 5; n=18, 18	14.0 Breaths per minute Standard Deviation 2.47	14.1 Breaths per minute Standard Deviation 1.75	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Sign: Temperature-Part 1 Day 2	36.22 Degrees Celsius Standard Deviation 0.426	36.39 Degrees Celsius Standard Deviation 0.407	—
Absolute Values for Vital Sign: Temperature-Part 1 Day 4	36.38 Degrees Celsius Standard Deviation 0.402	36.35 Degrees Celsius Standard Deviation 0.385	—
Absolute Values for Vital Sign: Temperature-Part 1 Day 5	36.21 Degrees Celsius Standard Deviation 0.555	36.27 Degrees Celsius Standard Deviation 0.324	—
Absolute Values for Vital Sign: Temperature-Part 1 Baseline	36.24 Degrees Celsius Standard Deviation 0.393	36.37 Degrees Celsius Standard Deviation 0.361	—
Absolute Values for Vital Sign: Temperature-Part 1 Day 3	36.33 Degrees Celsius Standard Deviation 0.420	36.22 Degrees Celsius Standard Deviation 0.383	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Baseline	74.8 Millimeters of mercury Standard Deviation 10.44	71.4 Millimeters of mercury Standard Deviation 9.62	71.8 Millimeters of mercury Standard Deviation 7.51
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Baseline	120.8 Millimeters of mercury Standard Deviation 17.53	115.2 Millimeters of mercury Standard Deviation 11.46	117.4 Millimeters of mercury Standard Deviation 13.01
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 2	117.4 Millimeters of mercury Standard Deviation 11.84	116.6 Millimeters of mercury Standard Deviation 11.32	115.7 Millimeters of mercury Standard Deviation 11.73
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 3	115.8 Millimeters of mercury Standard Deviation 10.63	117.2 Millimeters of mercury Standard Deviation 11.47	116.6 Millimeters of mercury Standard Deviation 12.36
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 4	119.0 Millimeters of mercury Standard Deviation 12.75	115.4 Millimeters of mercury Standard Deviation 11.14	118.0 Millimeters of mercury Standard Deviation 16.87
Absolute Values for Vital Signs: DBP and SBP-Part 2 SBP, Day 5	118.2 Millimeters of mercury Standard Deviation 12.92	115.8 Millimeters of mercury Standard Deviation 12.76	118.0 Millimeters of mercury Standard Deviation 13.18
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 2	72.5 Millimeters of mercury Standard Deviation 9.26	74.2 Millimeters of mercury Standard Deviation 9.83	71.1 Millimeters of mercury Standard Deviation 7.48
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 3	72.9 Millimeters of mercury Standard Deviation 7.57	72.9 Millimeters of mercury Standard Deviation 9.24	72.4 Millimeters of mercury Standard Deviation 7.53
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 4	71.9 Millimeters of mercury Standard Deviation 6.94	73.5 Millimeters of mercury Standard Deviation 8.32	70.5 Millimeters of mercury Standard Deviation 9.26
Absolute Values for Vital Signs: DBP and SBP-Part 2 DBP, Day 5	72.0 Millimeters of mercury Standard Deviation 8.61	72.3 Millimeters of mercury Standard Deviation 7.64	68.7 Millimeters of mercury Standard Deviation 9.18

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 2	66.9 Beats per minute Standard Deviation 12.76	64.0 Beats per minute Standard Deviation 10.66	64.1 Beats per minute Standard Deviation 7.94
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 3	66.7 Beats per minute Standard Deviation 11.28	64.9 Beats per minute Standard Deviation 14.16	67.4 Beats per minute Standard Deviation 11.04
Absolute Values for Vital Sign: Pulse Rate-Part 2 Baseline	65.4 Beats per minute Standard Deviation 12.47	64.1 Beats per minute Standard Deviation 7.70	63.8 Beats per minute Standard Deviation 7.85
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 4	70.8 Beats per minute Standard Deviation 12.90	68.2 Beats per minute Standard Deviation 11.25	72.6 Beats per minute Standard Deviation 12.36
Absolute Values for Vital Sign: Pulse Rate-Part 2 Day 5	67.6 Beats per minute Standard Deviation 11.19	69.1 Beats per minute Standard Deviation 9.11	69.6 Beats per minute Standard Deviation 13.99

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Baseline	14.8 Breaths per minute Standard Deviation 1.20	15.3 Breaths per minute Standard Deviation 2.02	13.8 Breaths per minute Standard Deviation 2.27
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 2	14.3 Breaths per minute Standard Deviation 2.27	15.4 Breaths per minute Standard Deviation 1.64	14.2 Breaths per minute Standard Deviation 2.36
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 3	15.0 Breaths per minute Standard Deviation 2.00	14.5 Breaths per minute Standard Deviation 1.98	14.2 Breaths per minute Standard Deviation 2.18
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 4	14.9 Breaths per minute Standard Deviation 2.38	14.0 Breaths per minute Standard Deviation 3.06	14.3 Breaths per minute Standard Deviation 2.22
Absolute Values for Vital Sign: Respiratory Rate-Part 2 Day 5	13.7 Breaths per minute Standard Deviation 1.63	14.5 Breaths per minute Standard Deviation 1.61	14.6 Breaths per minute Standard Deviation 1.80

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Vital Sign: Temperature-Part 2 Baseline	36.24 Degrees Celsius Standard Deviation 0.421	36.50 Degrees Celsius Standard Deviation 0.298	36.37 Degrees Celsius Standard Deviation 0.483
Absolute Values for Vital Sign: Temperature-Part 2 Day 2	36.29 Degrees Celsius Standard Deviation 0.476	36.40 Degrees Celsius Standard Deviation 0.406	36.27 Degrees Celsius Standard Deviation 0.508
Absolute Values for Vital Sign: Temperature-Part 2 Day 3	36.33 Degrees Celsius Standard Deviation 0.351	36.37 Degrees Celsius Standard Deviation 0.425	36.29 Degrees Celsius Standard Deviation 0.419
Absolute Values for Vital Sign: Temperature-Part 2 Day 4	36.37 Degrees Celsius Standard Deviation 0.404	36.37 Degrees Celsius Standard Deviation 0.378	36.38 Degrees Celsius Standard Deviation 0.495
Absolute Values for Vital Sign: Temperature-Part 2 Day 5	36.34 Degrees Celsius Standard Deviation 0.345	36.49 Degrees Celsius Standard Deviation 0.375	36.51 Degrees Celsius Standard Deviation 0.459

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 3	-1.7 Millimeters of mercury Standard Deviation 7.46	-4.3 Millimeters of mercury Standard Deviation 4.80	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 5	-2.1 Millimeters of mercury Standard Deviation 7.46	-4.6 Millimeters of mercury Standard Deviation 7.17	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 2	-4.5 Millimeters of mercury Standard Deviation 7.52	-2.3 Millimeters of mercury Standard Deviation 7.22	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 3	-4.7 Millimeters of mercury Standard Deviation 9.63	-4.1 Millimeters of mercury Standard Deviation 9.63	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 4	-6.1 Millimeters of mercury Standard Deviation 7.45	-3.4 Millimeters of mercury Standard Deviation 10.18	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 SBP; Day 5	-6.1 Millimeters of mercury Standard Deviation 7.49	-3.6 Millimeters of mercury Standard Deviation 11.37	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 2	-2.0 Millimeters of mercury Standard Deviation 6.82	-2.2 Millimeters of mercury Standard Deviation 5.78	—
Change From Baseline in Vital Signs: SBP and DBP-Part 1 DBP; Day 4	-1.9 Millimeters of mercury Standard Deviation 6.98	-4.7 Millimeters of mercury Standard Deviation 6.99	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 4	1.7 Beats per minute Standard Deviation 6.93	-0.6 Beats per minute Standard Deviation 7.88	—
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 2	1.1 Beats per minute Standard Deviation 5.76	2.2 Beats per minute Standard Deviation 7.50	—
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 3	1.8 Beats per minute Standard Deviation 8.20	2.4 Beats per minute Standard Deviation 7.41	—
Change From Baseline in Vital Sign: Pulse Rate-Part 1 Day 5	-1.3 Beats per minute Standard Deviation 5.46	0.8 Beats per minute Standard Deviation 10.70	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 2; n=17, 17	-1.1 Breaths per minute Standard Deviation 3.47	-0.8 Breaths per minute Standard Deviation 3.00	—
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 4; n=18, 18	-0.1 Breaths per minute Standard Deviation 2.78	-0.2 Breaths per minute Standard Deviation 3.35	—
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 3; n=17, 18	0.6 Breaths per minute Standard Deviation 2.62	0.3 Breaths per minute Standard Deviation 3.58	—
Change From Baseline in Vital Sign: Respiratory Rate-Part 1 Day 5; n=18, 18	0.0 Breaths per minute Standard Deviation 2.74	-0.8 Breaths per minute Standard Deviation 2.76	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Sign: Temperature-Part 1 Day 2	-0.03 Degrees Celsius Standard Deviation 0.329	0.02 Degrees Celsius Standard Deviation 0.472	—
Change From Baseline in Vital Sign: Temperature-Part 1 Day 3	0.09 Degrees Celsius Standard Deviation 0.442	-0.15 Degrees Celsius Standard Deviation 0.444	—
Change From Baseline in Vital Sign: Temperature-Part 1 Day 4	0.13 Degrees Celsius Standard Deviation 0.452	-0.02 Degrees Celsius Standard Deviation 0.458	—
Change From Baseline in Vital Sign: Temperature-Part 1 Day 5	-0.04 Degrees Celsius Standard Deviation 0.501	-0.11 Degrees Celsius Standard Deviation 0.330	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Blood pressure was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 2	-3.5 Millimeters of mercury Standard Deviation 10.50	1.5 Millimeters of mercury Standard Deviation 6.59	-1.7 Millimeters of mercury Standard Deviation 7.65
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 3	-5.1 Millimeters of mercury Standard Deviation 12.99	2.1 Millimeters of mercury Standard Deviation 7.74	-0.9 Millimeters of mercury Standard Deviation 9.11
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 4	-2.9 Millimeters of mercury Standard Deviation 8.53	2.2 Millimeters of mercury Standard Deviation 6.27	-1.3 Millimeters of mercury Standard Deviation 6.63
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 4	-1.9 Millimeters of mercury Standard Deviation 12.28	0.3 Millimeters of mercury Standard Deviation 6.10	0.6 Millimeters of mercury Standard Deviation 9.95
Change From Baseline in Vital Signs: SBP and DBP-Part 2 SBP, Day 5	-2.6 Millimeters of mercury Standard Deviation 11.23	0.7 Millimeters of mercury Standard Deviation 8.28	0.6 Millimeters of mercury Standard Deviation 7.71
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 2	-2.4 Millimeters of mercury Standard Deviation 6.10	2.8 Millimeters of mercury Standard Deviation 5.07	-0.7 Millimeters of mercury Standard Deviation 4.90
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 3	-1.9 Millimeters of mercury Standard Deviation 6.40	1.5 Millimeters of mercury Standard Deviation 7.83	0.6 Millimeters of mercury Standard Deviation 4.95
Change From Baseline in Vital Signs: SBP and DBP-Part 2 DBP, Day 5	-2.9 Millimeters of mercury Standard Deviation 6.19	0.9 Millimeters of mercury Standard Deviation 6.99	-3.0 Millimeters of mercury Standard Deviation 7.92

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Pulse rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 2	1.5 Beats per minute Standard Deviation 7.39	-0.1 Beats per minute Standard Deviation 8.02	0.3 Beats per minute Standard Deviation 4.72
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 3	1.3 Beats per minute Standard Deviation 9.69	0.9 Beats per minute Standard Deviation 13.16	3.7 Beats per minute Standard Deviation 6.59
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 4	5.4 Beats per minute Standard Deviation 10.17	4.1 Beats per minute Standard Deviation 9.64	8.9 Beats per minute Standard Deviation 8.21
Change From Baseline in Vital Sign: Pulse Rate-Part 2 Day 5	2.2 Beats per minute Standard Deviation 6.39	5.0 Beats per minute Standard Deviation 8.37	5.9 Beats per minute Standard Deviation 8.43

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Respiratory rate was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 2	-0.5 Breaths per minute Standard Deviation 2.24	0.1 Breaths per minute Standard Deviation 2.62	0.4 Breaths per minute Standard Deviation 2.58
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 3	0.2 Breaths per minute Standard Deviation 2.42	-0.7 Breaths per minute Standard Deviation 2.42	0.4 Breaths per minute Standard Deviation 3.61
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 4	0.1 Breaths per minute Standard Deviation 2.20	-1.3 Breaths per minute Standard Deviation 3.72	0.5 Breaths per minute Standard Deviation 2.27
Change From Baseline in Vital Sign: Respiratory Rate-Part 2 Day 5	-1.1 Breaths per minute Standard Deviation 1.77	-0.7 Breaths per minute Standard Deviation 1.91	0.8 Breaths per minute Standard Deviation 2.86

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), Days 2, 3, 4 and 5

Population: Safety Population

Temperature was assessed in the semi-recumbent position with a completely automated device, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the latest predose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Vital Sign: Temperature-Part 2 Day 4	0.13 Degrees Celsius Standard Deviation 0.490	-0.13 Degrees Celsius Standard Deviation 0.268	0.01 Degrees Celsius Standard Deviation 0.399
Change From Baseline in Vital Sign: Temperature-Part 2 Day 5	0.10 Degrees Celsius Standard Deviation 0.426	-0.01 Degrees Celsius Standard Deviation 0.375	0.15 Degrees Celsius Standard Deviation 0.437
Change From Baseline in Vital Sign: Temperature-Part 2 Day 2	0.05 Degrees Celsius Standard Deviation 0.477	-0.10 Degrees Celsius Standard Deviation 0.325	-0.10 Degrees Celsius Standard Deviation 0.390
Change From Baseline in Vital Sign: Temperature-Part 2 Day 3	0.09 Degrees Celsius Standard Deviation 0.302	-0.13 Degrees Celsius Standard Deviation 0.245	-0.08 Degrees Celsius Standard Deviation 0.453

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Lag Time for Absorption (Tlag) for GSK3640254-Part 1	0.528 Hours Standard Deviation 0.7568	0.139 Hours Standard Deviation 0.4132	—

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Apparent Terminal Phase Half-life (t1/2) for GSK3640254-Part 1	26.247 Hours Geometric Coefficient of Variation 17.6	26.185 Hours Geometric Coefficient of Variation 17.2	—

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Apparent Oral Clearance (CL/F) for GSK3640254-Part 1	5.413 Liters per hour Geometric Coefficient of Variation 42.7	5.423 Liters per hour Geometric Coefficient of Variation 40.3	—

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Apparent Volume of Distribution (Vz/F) for GSK3640254-Part 1	205.0 Liters Geometric Coefficient of Variation 40.0	204.9 Liters Geometric Coefficient of Variation 43.0	—

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Concentration Population comprised of all participants who underwent plasma PK sampling and had evaluable PK assay results.

Blood samples were collected at indicated time points for PK analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Plasma Concentration of GSK3640254-Part 1 pre-dose	1.910 Nanograms per milliliter Interval 0.0 to 44.1	1.580 Nanograms per milliliter Interval 0.0 to 31.5	—
Plasma Concentration of GSK3640254-Part 1 1 hour	6.795 Nanograms per milliliter Interval 0.0 to 80.8	81.90 Nanograms per milliliter Interval 0.0 to 842.0	—
Plasma Concentration of GSK3640254-Part 1 1.5 hours	26.40 Nanograms per milliliter Interval 0.0 to 421.0	291.0 Nanograms per milliliter Interval 0.0 to 1650.0	—
Plasma Concentration of GSK3640254-Part 1 2 hours	104.5 Nanograms per milliliter Interval 0.0 to 991.0	502.5 Nanograms per milliliter Interval 28.1 to 2160.0	—
Plasma Concentration of GSK3640254-Part 1 2.5 hours	342.5 Nanograms per milliliter Interval 0.0 to 1500.0	804.0 Nanograms per milliliter Interval 103.0 to 2610.0	—
Plasma Concentration of GSK3640254-Part 1 3 hours	563.5 Nanograms per milliliter Interval 16.7 to 1780.0	965.0 Nanograms per milliliter Interval 321.0 to 2210.0	—
Plasma Concentration of GSK3640254-Part 1 3.5 hours	724.0 Nanograms per milliliter Interval 44.3 to 1560.0	1105 Nanograms per milliliter Interval 482.0 to 2190.0	—
Plasma Concentration of GSK3640254-Part 1 4 hours	798.5 Nanograms per milliliter Interval 80.1 to 1660.0	1190 Nanograms per milliliter Interval 569.0 to 1940.0	—
Plasma Concentration of GSK3640254-Part 1 4.5 hours	964.5 Nanograms per milliliter Interval 135.0 to 1900.0	1270 Nanograms per milliliter Interval 567.0 to 1890.0	—
Plasma Concentration of GSK3640254-Part 1 5 hours	1047 Nanograms per milliliter Interval 170.0 to 1840.0	1195 Nanograms per milliliter Interval 479.0 to 1810.0	—
Plasma Concentration of GSK3640254-Part 1 6 hours	1013 Nanograms per milliliter Interval 385.0 to 1750.0	992.0 Nanograms per milliliter Interval 437.0 to 1710.0	—
Plasma Concentration of GSK3640254-Part 1 8 hours	981.0 Nanograms per milliliter Interval 298.0 to 1610.0	895.0 Nanograms per milliliter Interval 385.0 to 1500.0	—
Plasma Concentration of GSK3640254-Part 1 12 hours	817.0 Nanograms per milliliter Interval 253.0 to 1470.0	787.0 Nanograms per milliliter Interval 290.0 to 1210.0	—
Plasma Concentration of GSK3640254-Part 1 24 hours	565.5 Nanograms per milliliter Interval 162.0 to 889.0	582.0 Nanograms per milliliter Interval 202.0 to 887.0	—
Plasma Concentration of GSK3640254-Part 1 48 hours	286.0 Nanograms per milliliter Interval 81.9 to 483.0	286.0 Nanograms per milliliter Interval 121.0 to 509.0	—
Plasma Concentration of GSK3640254-Part 1 72 hours	159.0 Nanograms per milliliter Interval 47.3 to 284.0	150.0 Nanograms per milliliter Interval 75.1 to 271.0	—
Plasma Concentration of GSK3640254-Part 1 96 hours	78.10 Nanograms per milliliter Interval 26.0 to 197.0	72.80 Nanograms per milliliter Interval 34.0 to 172.0	—

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Tlag for GSK3640254-Part 2	0.050 Hours Standard Deviation 0.2236	0.000 Hours Standard Deviation 0.0000	0.048 Hours Standard Deviation 0.2182

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
T1/2 for GSK3640254-Part 2	24.921 Hours Geometric Coefficient of Variation 18.0	25.669 Hours Geometric Coefficient of Variation 12.7	24.833 Hours Geometric Coefficient of Variation 15.7

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
CL/F for GSK3640254-Part 2	4.878 Liter per hour Geometric Coefficient of Variation 42.2	14.85 Liter per hour Geometric Coefficient of Variation 58.2	5.417 Liter per hour Geometric Coefficient of Variation 35.9

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis. PK parameters were calculated using standard non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=10 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Vz/F for GSK3640254-Part 2	175.4 Liters Geometric Coefficient of Variation 43.4	550.1 Liters Geometric Coefficient of Variation 66.3	194.1 Liters Geometric Coefficient of Variation 35.9

SECONDARY outcome

Timeframe: pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Population: PK Concentration Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis.

Outcome measures

Outcome measures
Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=13 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Plasma Concentration of GSK3640254-Part 2 24 hours	627.5 Nanograms per milliliter Interval 256.0 to 1150.0	177.0 Nanograms per milliliter Interval 49.9 to 722.0	580.0 Nanograms per milliliter Interval 276.0 to 1070.0
Plasma Concentration of GSK3640254-Part 2 pre-dose	6.370 Nanograms per milliliter Interval 0.0 to 31.6	0 Nanograms per milliliter Interval 0.0 to 12.8	NA Nanograms per milliliter Interval to 14.7 Median and lower limit could not be calculated as the values were below the lower limit of quantification.
Plasma Concentration of GSK3640254-Part 2 1 hour	39.25 Nanograms per milliliter Interval 0.0 to 504.0	38.70 Nanograms per milliliter Interval 7.27 to 268.0	92.30 Nanograms per milliliter Interval 0.0 to 1960.0
Plasma Concentration of GSK3640254-Part 2 1.5 hours	306.0 Nanograms per milliliter Interval 9.18 to 1360.0	84.10 Nanograms per milliliter Interval 18.3 to 496.0	239.0 Nanograms per milliliter Interval 9.88 to 2000.0
Plasma Concentration of GSK3640254-Part 2 2 hours	733.0 Nanograms per milliliter Interval 37.7 to 1920.0	121.0 Nanograms per milliliter Interval 23.9 to 648.0	574.0 Nanograms per milliliter Interval 27.0 to 1790.0
Plasma Concentration of GSK3640254-Part 2 2.5 hours	1075 Nanograms per milliliter Interval 193.0 to 2320.0	194.0 Nanograms per milliliter Interval 31.0 to 831.0	684.0 Nanograms per milliliter Interval 65.0 to 1770.0
Plasma Concentration of GSK3640254-Part 2 3 hours	1195 Nanograms per milliliter Interval 434.0 to 2320.0	270.0 Nanograms per milliliter Interval 34.1 to 1050.0	724.0 Nanograms per milliliter Interval 125.0 to 2040.0
Plasma Concentration of GSK3640254-Part 2 3.5 hours	1250 Nanograms per milliliter Interval 525.0 to 2310.0	326.0 Nanograms per milliliter Interval 40.0 to 1260.0	785.0 Nanograms per milliliter Interval 212.0 to 2070.0
Plasma Concentration of GSK3640254-Part 2 4 hours	1305 Nanograms per milliliter Interval 607.0 to 2590.0	358.0 Nanograms per milliliter Interval 58.9 to 1270.0	833.0 Nanograms per milliliter Interval 230.0 to 1910.0
Plasma Concentration of GSK3640254-Part 2 4.5 hours	1245 Nanograms per milliliter Interval 636.0 to 2330.0	324.0 Nanograms per milliliter Interval 77.4 to 1480.0	866.0 Nanograms per milliliter Interval 272.0 to 1630.0
Plasma Concentration of GSK3640254-Part 2 5 hours	1275 Nanograms per milliliter Interval 590.0 to 2470.0	322.0 Nanograms per milliliter Interval 71.7 to 1420.0	845.0 Nanograms per milliliter Interval 355.0 to 1620.0
Plasma Concentration of GSK3640254-Part 2 6 hours	1195 Nanograms per milliliter Interval 528.0 to 2450.0	290.0 Nanograms per milliliter Interval 75.8 to 1350.0	968.0 Nanograms per milliliter Interval 562.0 to 1440.0
Plasma Concentration of GSK3640254-Part 2 8 hours	950.5 Nanograms per milliliter Interval 457.0 to 2110.0	255.0 Nanograms per milliliter Interval 57.9 to 1160.0	845.0 Nanograms per milliliter Interval 427.0 to 1370.0
Plasma Concentration of GSK3640254-Part 2 12 hours	773.0 Nanograms per milliliter Interval 363.0 to 1730.0	217.0 Nanograms per milliliter Interval 50.6 to 903.0	734.0 Nanograms per milliliter Interval 376.0 to 1420.0
Plasma Concentration of GSK3640254-Part 2 48 hours	335.5 Nanograms per milliliter Interval 123.0 to 533.0	98.60 Nanograms per milliliter Interval 35.4 to 327.0	287.0 Nanograms per milliliter Interval 149.0 to 683.0
Plasma Concentration of GSK3640254-Part 2 72 hours	171.5 Nanograms per milliliter Interval 57.7 to 292.0	52.50 Nanograms per milliliter Interval 28.3 to 153.0	145.0 Nanograms per milliliter Interval 68.0 to 375.0
Plasma Concentration of GSK3640254-Part 2 96 hours	79.75 Nanograms per milliliter Interval 26.4 to 203.0	31.30 Nanograms per milliliter Interval 14.8 to 80.7	62.20 Nanograms per milliliter Interval 35.9 to 224.0

Adverse Events

Part 1: GSK3640254 200 mg Capsules

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 1: GSK3640254 200 mg Tablets

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2: GSK3640254 200 mg Tablet (Moderate Fat)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 2: GSK3640254 200 mg Tablet (Fasted)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 2: GSK3640254 200 mg Tablet (High Fat)

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part 1: GSK3640254 200 mg Capsules n=18 participants at risk Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (Moderate Fat) n=20 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1, 2 or 3.	Part 2: GSK3640254 200 mg Tablet (Fasted) n=19 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under fasted conditions on Day 1 in Period 1, 2 or 3.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 participants at risk Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Eye disorders Eye irritation	0.00% 0/18 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	5.6% 1/18 • Number of events 1 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/20 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/19 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/21 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.
Gastrointestinal disorders Diarrhoea	0.00% 0/18 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/18 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/20 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	0.00% 0/19 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.	9.5% 2/21 • Number of events 2 • Up to Day 12 for Part 1 and up to Day 19 for Part 2 AEs and SAEs were collected in the Safety Population which comprised of all participants who received at least 1 dose of study medication. Data is presented treatment-wise.

Additional Information

GSK Response Center

ViiV Healthcare

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 5; n=9, 9	0.133 10^9 cells per liter Standard Deviation 0.1227	0.118 10^9 cells per liter Standard Deviation 0.0769	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Baseline; n=18, 18	0.032 10^9 cells per liter Standard Deviation 0.0134	0.032 10^9 cells per liter Standard Deviation 0.0134	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 2; n=18, 18	0.030 10^9 cells per liter Standard Deviation 0.0137	0.030 10^9 cells per liter Standard Deviation 0.077	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Basophils; Day 5; n=9, 9	0.027 10^9 cells per liter Standard Deviation 0.0071	0.030 10^9 cells per liter Standard Deviation 0.0166	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Baseline; n=18, 18	0.100 10^9 cells per liter Standard Deviation 0.0832	0.100 10^9 cells per liter Standard Deviation 0.0832	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Eosinophils; Day 2; n=18, 18	0.116 10^9 cells per liter Standard Deviation 0.0911	0.122 10^9 cells per liter Standard Deviation 0.1101	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Baseline; n=18, 18	1.617 10^9 cells per liter Standard Deviation 0.3975	1.617 10^9 cells per liter Standard Deviation 0.3975	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 2; n=18, 18	1.726 10^9 cells per liter Standard Deviation 0.3852	1.744 10^9 cells per liter Standard Deviation 0.4791	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Lymphocytes; Day 5; n=9, 9	1.639 10^9 cells per liter Standard Deviation 0.3536	2.074 10^9 cells per liter Standard Deviation 0.6328	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Baseline; n=18, 18	0.403 10^9 cells per liter Standard Deviation 0.0859	0.403 10^9 cells per liter Standard Deviation 0.0859	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 2; n=18, 18	0.409 10^9 cells per liter Standard Deviation 0.0955	0.412 10^9 cells per liter Standard Deviation 0.1379	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Monocytes; Day 5; n=9, 9	0.386 10^9 cells per liter Standard Deviation 0.1100	0.411 10^9 cells per liter Standard Deviation 0.1071	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Baseline; n=18, 18	3.406 10^9 cells per liter Standard Deviation 1.0436	3.406 10^9 cells per liter Standard Deviation 1.0436	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 2; n=18, 18	2.925 10^9 cells per liter Standard Deviation 0.6617	2.723 10^9 cells per liter Standard Deviation 0.9257	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Neutrophils; Day 5; n=9, 9	2.864 10^9 cells per liter Standard Deviation 0.7372	3.108 10^9 cells per liter Standard Deviation 0.5724	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Baseline; n=18, 18	232.5 10^9 cells per liter Standard Deviation 43.58	232.5 10^9 cells per liter Standard Deviation 43.58	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 2; n=18, 18	238.2 10^9 cells per liter Standard Deviation 49.37	241.5 10^9 cells per liter Standard Deviation 48.56	—
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 1 Platelets; Day 5; n=9, 9	267.1 10^9 cells per liter Standard Deviation 52.86	231.4 10^9 cells per liter Standard Deviation 38.51	—

Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 5; n=7, 5, 7	1.806 10^9 cells per liter Standard Deviation 0.3577	1.472 10^9 cells per liter Standard Deviation 0.2765	1.923 10^9 cells per liter Standard Deviation 0.4442
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Baseline; n=20, 19, 21	0.469 10^9 cells per liter Standard Deviation 0.1445	0.469 10^9 cells per liter Standard Deviation 0.1445	0.469 10^9 cells per liter Standard Deviation 0.1445
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 2; n=20, 19, 21	0.446 10^9 cells per liter Standard Deviation 0.1589	0.449 10^9 cells per liter Standard Deviation 0.1171	0.446 10^9 cells per liter Standard Deviation 0.1553
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Monocytes; Day 5; n=7, 5, 7	0.530 10^9 cells per liter Standard Deviation 0.1788	0.422 10^9 cells per liter Standard Deviation 0.0669	0.504 10^9 cells per liter Standard Deviation 0.1130
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Baseline; n=20, 19, 21	0.042 10^9 cells per liter Standard Deviation 0.0260	0.042 10^9 cells per liter Standard Deviation 0.0260	0.042 10^9 cells per liter Standard Deviation 0.0260
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 2; n=20, 19, 21	0.041 10^9 cells per liter Standard Deviation 0.0276	0.040 10^9 cells per liter Standard Deviation 0.0200	0.043 10^9 cells per liter Standard Deviation 0.0215
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Basophils; Day 5; n=7, 5, 7	0.047 10^9 cells per liter Standard Deviation 0.0287	0.036 10^9 cells per liter Standard Deviation 0.0167	0.049 10^9 cells per liter Standard Deviation 0.0219
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Baseline; n=20, 19, 21	0.141 10^9 cells per liter Standard Deviation 0.0879	0.141 10^9 cells per liter Standard Deviation 0.0879	0.141 10^9 cells per liter Standard Deviation 0.0879
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 2; n=20, 19, 21	0.136 10^9 cells per liter Standard Deviation 0.0922	0.135 10^9 cells per liter Standard Deviation 0.0837	0.150 10^9 cells per liter Standard Deviation 0.1109
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Eosinophils; Day 5; n=7, 5, 7	0.146 10^9 cells per liter Standard Deviation 0.1050	0.090 10^9 cells per liter Standard Deviation 0.0374	0.151 10^9 cells per liter Standard Deviation 0.0915
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Baseline; n=20, 19, 21	1.650 10^9 cells per liter Standard Deviation 0.4926	1.650 10^9 cells per liter Standard Deviation 0.4926	1.650 10^9 cells per liter Standard Deviation 0.4926
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Lymphocytes; Day 2; n=20, 19, 21	1.576 10^9 cells per liter Standard Deviation 0.3410	1.684 10^9 cells per liter Standard Deviation 0.4939	1.583 10^9 cells per liter Standard Deviation 0.3748
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Baseline; n=20, 19, 21	3.246 10^9 cells per liter Standard Deviation 1.0719	3.246 10^9 cells per liter Standard Deviation 1.0719	3.246 10^9 cells per liter Standard Deviation 1.0719
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 2; n=20, 19, 21	2.908 10^9 cells per liter Standard Deviation 1.1660	2.904 10^9 cells per liter Standard Deviation 0.8595	2.947 10^9 cells per liter Standard Deviation 1.0824
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Neutrophils; Day 5; n=7, 5, 7	2.464 10^9 cells per liter Standard Deviation 0.9204	3.472 10^9 cells per liter Standard Deviation 0.8987	3.877 10^9 cells per liter Standard Deviation 1.4452
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Baseline; n=20, 19, 21	259.9 10^9 cells per liter Standard Deviation 63.91	259.9 10^9 cells per liter Standard Deviation 63.91	259.9 10^9 cells per liter Standard Deviation 63.91
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 2; n=20, 19, 21	284.2 10^9 cells per liter Standard Deviation 55.70	270.6 10^9 cells per liter Standard Deviation 60.80	281.3 10^9 cells per liter Standard Deviation 59.88
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets-Part 2 Platelets; Day 5; n=7, 5, 7	255.9 10^9 cells per liter Standard Deviation 47.27	272.4 10^9 cells per liter Standard Deviation 77.61	291.3 10^9 cells per liter Standard Deviation 48.52

Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Baseline; n=18, 18	3.728 Millimoles per liter Standard Deviation 1.0672	3.728 Millimoles per liter Standard Deviation 1.0672	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 2; n=18, 18	1.127 Millimoles per liter Standard Deviation 0.3973	1.036 Millimoles per liter Standard Deviation 0.3982	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Baseline; n=18, 18	4.549 Millimoles per liter Standard Deviation 0.9656	4.549 Millimoles per liter Standard Deviation 0.9656	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 2; n=18, 18	30.1 Millimoles per liter Standard Deviation 1.86	30.2 Millimoles per liter Standard Deviation 1.58	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Baseline; n=18, 18	2.327 Millimoles per liter Standard Deviation 0.0451	2.327 Millimoles per liter Standard Deviation 0.0451	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 2; n=18, 18	2.352 Millimoles per liter Standard Deviation 0.0536	2.378 Millimoles per liter Standard Deviation 0.0830	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 5; n=9, 9	2.343 Millimoles per liter Standard Deviation 0.0705	2.313 Millimoles per liter Standard Deviation 0.0559	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Baseline; n=18, 18	4.987 Millimoles per liter Standard Deviation 0.3833	4.987 Millimoles per liter Standard Deviation 0.3833	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 2; n=18, 18	4.842 Millimoles per liter Standard Deviation 0.3451	4.706 Millimoles per liter Standard Deviation 0.2996	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 5; n=9, 9	4.607 Millimoles per liter Standard Deviation 0.2889	4.600 Millimoles per liter Standard Deviation 0.2182	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Baseline; n=18, 18	4.00 Millimoles per liter Standard Deviation 0.230	4.00 Millimoles per liter Standard Deviation 0.230	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 2; n=18, 18	4.27 Millimoles per liter Standard Deviation 0.256	4.33 Millimoles per liter Standard Deviation 0.379	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 5; n=9, 9	4.18 Millimoles per liter Standard Deviation 0.228	4.13 Millimoles per liter Standard Deviation 0.320	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Baseline; n=18, 18	136.9 Millimoles per liter Standard Deviation 2.19	136.9 Millimoles per liter Standard Deviation 2.19	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 2; n=18, 18	138.5 Millimoles per liter Standard Deviation 1.54	138.9 Millimoles per liter Standard Deviation 1.75	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 5; n=9, 9	138.2 Millimoles per liter Standard Deviation 1.48	138.8 Millimoles per liter Standard Deviation 1.48	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Baseline; n=18, 18	102.3 Millimoles per liter Standard Deviation 1.64	102.3 Millimoles per liter Standard Deviation 1.64	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 2; n=18, 18	102.5 Millimoles per liter Standard Deviation 1.69	102.9 Millimoles per liter Standard Deviation 1.66	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 5; n=9, 9	101.9 Millimoles per liter Standard Deviation 1.76	101.8 Millimoles per liter Standard Deviation 1.56	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Baseline; n=18, 18	1.121 Millimoles per liter Standard Deviation 0.1289	1.121 Millimoles per liter Standard Deviation 0.1289	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 2; n=18, 18	1.197 Millimoles per liter Standard Deviation 0.1058	1.197 Millimoles per liter Standard Deviation 0.1365	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 5; n=9, 9	1.173 Millimoles per liter Standard Deviation 0.1413	1.234 Millimoles per liter Standard Deviation 0.0963	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 2; n=18, 18	4.747 Millimoles per liter Standard Deviation 0.8949	4.654 Millimoles per liter Standard Deviation 0.8997	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 5; n=9, 9	5.053 Millimoles per liter Standard Deviation 0.9143	4.729 Millimoles per liter Standard Deviation 0.7928	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Baseline; n=18, 18	1.026 Millimoles per liter Standard Deviation 0.6064	1.026 Millimoles per liter Standard Deviation 0.6064	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 5; n=9, 9	1.029 Millimoles per liter Standard Deviation 0.3389	0.904 Millimoles per liter Standard Deviation 0.2605	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 2; n=18, 18	4.544 Millimoles per liter Standard Deviation 0.8853	4.632 Millimoles per liter Standard Deviation 0.9164	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 5; n=9, 9	4.519 Millimoles per liter Standard Deviation 0.6212	4.330 Millimoles per liter Standard Deviation 1.1611	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Baseline; n=18, 18	9.5 Millimoles per liter Standard Deviation 1.76	9.5 Millimoles per liter Standard Deviation 1.76	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 2; n=18, 18	10.1 Millimoles per liter Standard Deviation 1.28	10.0 Millimoles per liter Standard Deviation 1.08	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 5; n=9, 9	10.7 Millimoles per liter Standard Deviation 0.87	10.1 Millimoles per liter Standard Deviation 0.93	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Baseline; n=18, 18	29.1 Millimoles per liter Standard Deviation 2.00	29.1 Millimoles per liter Standard Deviation 2.00	—
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, Blood Urea Nitrogen (BUN), Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 5; n=9, 9	29.9 Millimoles per liter Standard Deviation 1.36	31.0 Millimoles per liter Standard Deviation 1.87	—

Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALT; Baseline; n=18, 18	22.1 International units per liter Standard Deviation 12.44	22.1 International units per liter Standard Deviation 12.44	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALT; Day 2; n=18, 18	21.8 International units per liter Standard Deviation 13.38	18.4 International units per liter Standard Deviation 9.28	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALT; Day 5; n=9, 9	20.6 International units per liter Standard Deviation 14.51	19.6 International units per liter Standard Deviation 7.07	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALP; Baseline; n=18, 18	54.6 International units per liter Standard Deviation 11.32	54.6 International units per liter Standard Deviation 11.32	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALP; Day 2; n=18, 18	52.1 International units per liter Standard Deviation 11.59	52.1 International units per liter Standard Deviation 10.96	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 ALP; Day 5; n=9, 9	55.2 International units per liter Standard Deviation 12.34	50.3 International units per liter Standard Deviation 5.87	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 AST; Baseline; n=18, 18	21.7 International units per liter Standard Deviation 8.39	21.7 International units per liter Standard Deviation 8.39	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 AST; Day 2; n=18, 18	19.1 International units per liter Standard Deviation 6.65	17.6 International units per liter Standard Deviation 4.94	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 AST; Day 5; n=9, 9	19.0 International units per liter Standard Deviation 4.30	17.0 International units per liter Standard Deviation 3.71	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 GGT; Baseline; n=18, 18	19.3 International units per liter Standard Deviation 11.26	19.3 International units per liter Standard Deviation 11.26	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 GGT; Day 2; n=18, 18	18.1 International units per liter Standard Deviation 11.18	18.9 International units per liter Standard Deviation 11.60	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 GGT; Day 5; n=9, 9	19.2 International units per liter Standard Deviation 13.07	15.8 International units per liter Standard Deviation 6.85	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 CK; Baseline; n=18, 18	126.9 International units per liter Standard Deviation 62.61	126.9 International units per liter Standard Deviation 62.61	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 CK; Day 2; n=18, 18	87.4 International units per liter Standard Deviation 40.30	92.2 International units per liter Standard Deviation 44.64	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 CK; Day 5; n=9, 9	86.0 International units per liter Standard Deviation 35.27	98.3 International units per liter Standard Deviation 50.21	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 LDH; Baseline; n=18, 18	136.4 International units per liter Standard Deviation 20.82	136.4 International units per liter Standard Deviation 20.82	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 LDH; Day 2; n=18, 18	117.7 International units per liter Standard Deviation 21.06	120.4 International units per liter Standard Deviation 21.17	—
Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase (CK), Lactate Dehydrogenase (LDH)-Part 1 LDH; Day 5; n=9, 9	122.0 International units per liter Standard Deviation 20.91	123.6 International units per liter Standard Deviation 18.53	—

Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 2; n=20, 19, 21	0.957 Millimoles per liter Standard Deviation 0.3872	0.994 Millimoles per liter Standard Deviation 0.3875	0.890 Millimoles per liter Standard Deviation 0.4024
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Baseline; n=20, 19, 21	2.312 Millimoles per liter Standard Deviation 0.0973	2.312 Millimoles per liter Standard Deviation 0.0973	2.312 Millimoles per liter Standard Deviation 0.0973
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 2; n=20, 19, 21	2.408 Millimoles per liter Standard Deviation 0.0670	2.369 Millimoles per liter Standard Deviation 0.0671	2.390 Millimoles per liter Standard Deviation 0.0695
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 5; n=7, 5, 7	2.446 Millimoles per liter Standard Deviation 0.0500	2.324 Millimoles per liter Standard Deviation 0.0439	2.367 Millimoles per liter Standard Deviation 0.0640
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Baseline; n=20, 19, 21	4.745 Millimoles per liter Standard Deviation 0.3160	4.745 Millimoles per liter Standard Deviation 0.3160	4.745 Millimoles per liter Standard Deviation 0.3160
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 2; n=20, 19, 21	4.716 Millimoles per liter Standard Deviation 0.2093	4.861 Millimoles per liter Standard Deviation 0.2250	4.775 Millimoles per liter Standard Deviation 0.2039
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 5; n=7, 5, 7	4.574 Millimoles per liter Standard Deviation 0.3675	4.608 Millimoles per liter Standard Deviation 0.3518	4.926 Millimoles per liter Standard Deviation 0.2224
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Baseline; n=20, 19, 21	4.16 Millimoles per liter Standard Deviation 0.225	4.16 Millimoles per liter Standard Deviation 0.225	4.16 Millimoles per liter Standard Deviation 0.225
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 2; n=20, 19, 21	4.26 Millimoles per liter Standard Deviation 0.244	4.17 Millimoles per liter Standard Deviation 0.281	4.14 Millimoles per liter Standard Deviation 0.240
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 5; n=7, 5, 7	3.84 Millimoles per liter Standard Deviation 0.251	3.94 Millimoles per liter Standard Deviation 0.230	4.17 Millimoles per liter Standard Deviation 0.236
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Baseline; n=20, 19, 21	138.4 Millimoles per liter Standard Deviation 1.56	138.4 Millimoles per liter Standard Deviation 1.56	138.4 Millimoles per liter Standard Deviation 1.56
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 2; n=20, 19, 21	137.9 Millimoles per liter Standard Deviation 2.00	137.9 Millimoles per liter Standard Deviation 2.58	137.4 Millimoles per liter Standard Deviation 1.24
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 5; n=7, 5, 7	137.3 Millimoles per liter Standard Deviation 1.11	136.2 Millimoles per liter Standard Deviation 2.59	136.3 Millimoles per liter Standard Deviation 1.89
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Baseline; n=20, 19, 21	102.4 Millimoles per liter Standard Deviation 1.72	102.4 Millimoles per liter Standard Deviation 1.72	102.4 Millimoles per liter Standard Deviation 1.72
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 2; n=20, 19, 21	102.0 Millimoles per liter Standard Deviation 1.81	102.2 Millimoles per liter Standard Deviation 2.06	102.0 Millimoles per liter Standard Deviation 2.09
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 5; n=7, 5, 7	100.3 Millimoles per liter Standard Deviation 1.38	101.8 Millimoles per liter Standard Deviation 2.28	100.4 Millimoles per liter Standard Deviation 2.37
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Baseline; n=20, 19, 21	1.100 Millimoles per liter Standard Deviation 0.1813	1.100 Millimoles per liter Standard Deviation 0.1813	1.100 Millimoles per liter Standard Deviation 0.1813
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 2; n=20, 19, 21	1.191 Millimoles per liter Standard Deviation 0.1827	1.177 Millimoles per liter Standard Deviation 0.1535	1.176 Millimoles per liter Standard Deviation 0.1730
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 5; n=7, 5, 7	1.297 Millimoles per liter Standard Deviation 0.1577	1.158 Millimoles per liter Standard Deviation 0.2958	1.117 Millimoles per liter Standard Deviation 0.1612
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Baseline; n=20, 19, 21	4.190 Millimoles per liter Standard Deviation 0.9187	4.190 Millimoles per liter Standard Deviation 0.9187	4.190 Millimoles per liter Standard Deviation 0.9187
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 2; n=20, 19, 21	4.526 Millimoles per liter Standard Deviation 0.7144	4.531 Millimoles per liter Standard Deviation 0.8261	4.403 Millimoles per liter Standard Deviation 0.8736
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 5; n=7, 5, 7	4.921 Millimoles per liter Standard Deviation 0.9744	4.768 Millimoles per liter Standard Deviation 0.4098	5.050 Millimoles per liter Standard Deviation 1.2701
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Baseline; n=20, 19, 21	0.828 Millimoles per liter Standard Deviation 0.3752	0.828 Millimoles per liter Standard Deviation 0.3752	0.828 Millimoles per liter Standard Deviation 0.3752
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 5; n=7, 5, 7	0.894 Millimoles per liter Standard Deviation 0.3072	0.774 Millimoles per liter Standard Deviation 0.2790	1.363 Millimoles per liter Standard Deviation 0.6417
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Baseline; n=20, 19, 21	4.533 Millimoles per liter Standard Deviation 0.8776	4.533 Millimoles per liter Standard Deviation 0.8776	4.533 Millimoles per liter Standard Deviation 0.8776
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 2; n=20, 19, 21	4.652 Millimoles per liter Standard Deviation 0.7742	4.639 Millimoles per liter Standard Deviation 0.9975	4.610 Millimoles per liter Standard Deviation 0.8031
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 5; n=7, 5, 7	4.520 Millimoles per liter Standard Deviation 0.5269	3.962 Millimoles per liter Standard Deviation 0.8236	4.454 Millimoles per liter Standard Deviation 0.8948
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Baseline; n=20, 19, 21	11.3 Millimoles per liter Standard Deviation 1.53	11.3 Millimoles per liter Standard Deviation 1.53	11.3 Millimoles per liter Standard Deviation 1.53
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 2; n=20, 19, 21	10.6 Millimoles per liter Standard Deviation 1.15	10.4 Millimoles per liter Standard Deviation 1.17	10.8 Millimoles per liter Standard Deviation 1.54
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 5; n=7, 5, 7	11.7 Millimoles per liter Standard Deviation 2.43	10.8 Millimoles per liter Standard Deviation 0.84	11.9 Millimoles per liter Standard Deviation 1.68
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Baseline; n=20, 19, 21	28.7 Millimoles per liter Standard Deviation 2.00	28.7 Millimoles per liter Standard Deviation 2.00	28.7 Millimoles per liter Standard Deviation 2.00
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 2; n=20, 19, 21	29.6 Millimoles per liter Standard Deviation 1.67	29.5 Millimoles per liter Standard Deviation 1.78	28.6 Millimoles per liter Standard Deviation 2.20
Absolute Values for Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 5; n=7, 5, 7	29.3 Millimoles per liter Standard Deviation 1.50	27.6 Millimoles per liter Standard Deviation 2.19	28.1 Millimoles per liter Standard Deviation 1.57

Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 2; n=20, 19, 21	56.5 International units per liter Standard Deviation 17.52	57.4 International units per liter Standard Deviation 17.03	56.7 International units per liter Standard Deviation 18.33
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Day 5; n=7, 5, 7	49.6 International units per liter Standard Deviation 22.40	56.4 International units per liter Standard Deviation 9.58	55.0 International units per liter Standard Deviation 13.69
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Baseline; n=20, 19, 21	19.0 International units per liter Standard Deviation 11.01	19.0 International units per liter Standard Deviation 11.01	19.0 International units per liter Standard Deviation 11.01
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 2; n=20, 19, 21	14.4 International units per liter Standard Deviation 6.06	17.3 International units per liter Standard Deviation 9.49	16.8 International units per liter Standard Deviation 9.20
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALT; Day 5; n=7, 5, 7	16.7 International units per liter Standard Deviation 8.04	11.0 International units per liter Standard Deviation 2.74	22.7 International units per liter Standard Deviation 14.36
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 ALP; Baseline; n=20, 19, 21	50.4 International units per liter Standard Deviation 16.47	50.4 International units per liter Standard Deviation 16.47	50.4 International units per liter Standard Deviation 16.47
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Baseline; n=20, 19, 21	18.0 International units per liter Standard Deviation 6.01	18.0 International units per liter Standard Deviation 6.01	18.0 International units per liter Standard Deviation 6.01
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 2; n=20, 19, 21	14.9 International units per liter Standard Deviation 3.01	15.8 International units per liter Standard Deviation 4.29	16.0 International units per liter Standard Deviation 4.11
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 AST; Day 5; n=7, 5, 7	16.7 International units per liter Standard Deviation 4.42	14.0 International units per liter Standard Deviation 2.12	16.6 International units per liter Standard Deviation 3.78
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Baseline; n=20, 19, 21	17.1 International units per liter Standard Deviation 5.80	17.1 International units per liter Standard Deviation 5.80	17.1 International units per liter Standard Deviation 5.80
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 2; n=20, 19, 21	16.5 International units per liter Standard Deviation 5.56	17.4 International units per liter Standard Deviation 6.15	17.3 International units per liter Standard Deviation 7.67
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 GGT; Day 5; n=7, 5, 7	14.9 International units per liter Standard Deviation 3.72	14.8 International units per liter Standard Deviation 0.45	21.6 International units per liter Standard Deviation 13.31
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Baseline; n=20, 19, 21	118.8 International units per liter Standard Deviation 79.80	118.8 International units per liter Standard Deviation 79.80	118.8 International units per liter Standard Deviation 79.80
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 2; n=20, 19, 21	106.2 International units per liter Standard Deviation 80.82	114.9 International units per liter Standard Deviation 101.61	106.2 International units per liter Standard Deviation 81.94
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 CK; Day 5; n=7, 5, 7	135.7 International units per liter Standard Deviation 108.77	136.4 International units per liter Standard Deviation 109.71	145.4 International units per liter Standard Deviation 170.90
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Baseline; n=20, 19, 21	133.6 International units per liter Standard Deviation 19.21	133.6 International units per liter Standard Deviation 19.21	133.6 International units per liter Standard Deviation 19.21
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 2; n=20, 19, 21	121.1 International units per liter Standard Deviation 17.48	121.5 International units per liter Standard Deviation 21.60	122.1 International units per liter Standard Deviation 18.56
Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, CK, LDH-Part 2 LDH; Day 5; n=7, 5, 7	118.4 International units per liter Standard Deviation 16.63	110.0 International units per liter Standard Deviation 12.29	126.0 International units per liter Standard Deviation 22.84

Measure	Part 1: GSK3640254 200 mg Capsules n=18 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=18 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 2; n=18, 18	0.9 Millimoles per liter Standard Deviation 2.60	1.1 Millimoles per liter Standard Deviation 2.10	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Carbon dioxide; Day 5; n=9, 9	1.4 Millimoles per liter Standard Deviation 2.60	1.2 Millimoles per liter Standard Deviation 1.56	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 2; n=18, 18	0.025 Millimoles per liter Standard Deviation 0.0534	0.051 Millimoles per liter Standard Deviation 0.0828	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Calcium; Day 5; n=9, 9	0.019 Millimoles per liter Standard Deviation 0.0762	-0.016 Millimoles per liter Standard Deviation 0.0548	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 2; n=18, 18	-0.145 Millimoles per liter Standard Deviation 0.3134	-0.281 Millimoles per liter Standard Deviation 0.4796	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Glucose; Day 5; n=9, 9	-0.252 Millimoles per liter Standard Deviation 0.4474	-0.514 Millimoles per liter Standard Deviation 0.3475	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 2; n=18, 18	0.27 Millimoles per liter Standard Deviation 0.278	0.33 Millimoles per liter Standard Deviation 0.331	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Potassium; Day 5; n=9, 9	0.30 Millimoles per liter Standard Deviation 0.296	0.01 Millimoles per liter Standard Deviation 0.247	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 2; n=18, 18	1.6 Millimoles per liter Standard Deviation 2.30	2.0 Millimoles per liter Standard Deviation 2.28	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Sodium; Day 5; n=9, 9	1.8 Millimoles per liter Standard Deviation 2.77	1.4 Millimoles per liter Standard Deviation 1.33	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 2; n=18, 18	0.2 Millimoles per liter Standard Deviation 2.05	0.7 Millimoles per liter Standard Deviation 2.22	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Chloride; Day 5; n=9, 9	-0.2 Millimoles per liter Standard Deviation 2.33	-0.7 Millimoles per liter Standard Deviation 1.73	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 2; n=18, 18	0.077 Millimoles per liter Standard Deviation 0.1177	0.077 Millimoles per liter Standard Deviation 0.1223	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Phosphate; Day 5; n=9, 9	0.077 Millimoles per liter Standard Deviation 0.1331	0.090 Millimoles per liter Standard Deviation 0.1282	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 2; n=18, 18	1.019 Millimoles per liter Standard Deviation 0.9553	0.926 Millimoles per liter Standard Deviation 1.0408	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 BUN; Day 5; n=9, 9	1.178 Millimoles per liter Standard Deviation 1.0554	1.148 Millimoles per liter Standard Deviation 0.6297	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 2; n=18, 18	0.101 Millimoles per liter Standard Deviation 0.4182	0.010 Millimoles per liter Standard Deviation 0.4769	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Triglycerides; Day 5; n=9, 9	0.102 Millimoles per liter Standard Deviation 0.2870	-0.221 Millimoles per liter Standard Deviation 0.5382	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 2; n=18, 18	-0.005 Millimoles per liter Standard Deviation 0.3983	0.082 Millimoles per liter Standard Deviation 0.4981	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Cholesterol; Day 5; n=9, 9	-0.148 Millimoles per liter Standard Deviation 0.4463	-0.102 Millimoles per liter Standard Deviation 0.6612	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 2; n=18, 18	0.6 Millimoles per liter Standard Deviation 2.03	0.5 Millimoles per liter Standard Deviation 1.95	—
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 1 Anion gap; Day 5; n=9, 9	0.8 Millimoles per liter Standard Deviation 2.64	1.0 Millimoles per liter Standard Deviation 1.22	—

Measure	Part 1: GSK3640254 200 mg Capsules n=20 Participants Participants were administered a single dose of GSK3640254 200 mg capsules, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 1: GSK3640254 200 mg Tablets n=19 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under moderate fat conditions on Day 1 in Period 1 or 2.	Part 2: GSK3640254 200 mg Tablet (High Fat) n=21 Participants Participants were administered a single dose of GSK3640254 200 mg tablets, orally under high fat conditions on Day 1 in Period 1, 2 or 3.
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 2; n=20, 19, 21	-0.036 Millimoles per liter Standard Deviation 0.2823	0.087 Millimoles per liter Standard Deviation 0.2938	0.030 Millimoles per liter Standard Deviation 0.2588
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 5; n=7, 5, 7	-0.26 Millimoles per liter Standard Deviation 0.270	-0.32 Millimoles per liter Standard Deviation 0.377	-0.04 Millimoles per liter Standard Deviation 0.282
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 5; n=7, 5, 7	-1.9 Millimoles per liter Standard Deviation 0.69	-2.0 Millimoles per liter Standard Deviation 1.41	-1.4 Millimoles per liter Standard Deviation 3.10
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 2; n=20, 19, 21	0.307 Millimoles per liter Standard Deviation 0.8732	0.257 Millimoles per liter Standard Deviation 0.9884	0.213 Millimoles per liter Standard Deviation 0.9258
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 2; n=20, 19, 21	0.098 Millimoles per liter Standard Deviation 0.0777	0.063 Millimoles per liter Standard Deviation 0.0930	0.078 Millimoles per liter Standard Deviation 0.0590
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Calcium; Day 5; n=7, 5, 7	0.097 Millimoles per liter Standard Deviation 0.0663	0.068 Millimoles per liter Standard Deviation 0.0867	0.067 Millimoles per liter Standard Deviation 0.0702
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Glucose; Day 5; n=7, 5, 7	-0.207 Millimoles per liter Standard Deviation 0.3073	-0.100 Millimoles per liter Standard Deviation 0.2547	0.113 Millimoles per liter Standard Deviation 0.3935
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Potassium; Day 2; n=20, 19, 21	0.08 Millimoles per liter Standard Deviation 0.249	-0.01 Millimoles per liter Standard Deviation 0.273	-0.02 Millimoles per liter Standard Deviation 0.270
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Sodium; Day 2; n=20, 19, 21	-0.5 Millimoles per liter Standard Deviation 2.06	-0.5 Millimoles per liter Standard Deviation 2.59	-1.0 Millimoles per liter Standard Deviation 2.00
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 2; n=20, 19, 21	-0.5 Millimoles per liter Standard Deviation 1.67	-0.2 Millimoles per liter Standard Deviation 1.78	-0.3 Millimoles per liter Standard Deviation 2.29
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Chloride; Day 5; n=7, 5, 7	-1.9 Millimoles per liter Standard Deviation 0.90	-2.2 Millimoles per liter Standard Deviation 1.10	-1.0 Millimoles per liter Standard Deviation 2.89
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 2; n=20, 19, 21	0.087 Millimoles per liter Standard Deviation 0.0836	0.065 Millimoles per liter Standard Deviation 0.0973	0.076 Millimoles per liter Standard Deviation 0.0815
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Phosphate; Day 5; n=7, 5, 7	0.060 Millimoles per liter Standard Deviation 0.0856	0.124 Millimoles per liter Standard Deviation 0.0953	0.074 Millimoles per liter Standard Deviation 0.0820
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 BUN; Day 5; n=7, 5, 7	0.783 Millimoles per liter Standard Deviation 1.1942	0.684 Millimoles per liter Standard Deviation 0.7695	0.506 Millimoles per liter Standard Deviation 0.9007
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 2; n=20, 19, 21	0.115 Millimoles per liter Standard Deviation 0.2130	0.127 Millimoles per liter Standard Deviation 0.2750	0.062 Millimoles per liter Standard Deviation 0.2884
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Triglycerides; Day 5; n=7, 5, 7	0.021 Millimoles per liter Standard Deviation 0.2874	0.226 Millimoles per liter Standard Deviation 0.1254	0.273 Millimoles per liter Standard Deviation 0.5007
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 2; n=20, 19, 21	0.103 Millimoles per liter Standard Deviation 0.4625	0.078 Millimoles per liter Standard Deviation 0.5175	0.077 Millimoles per liter Standard Deviation 0.4478
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Cholesterol; Day 5; n=7, 5, 7	-0.033 Millimoles per liter Standard Deviation 0.5333	-0.286 Millimoles per liter Standard Deviation 0.3791	-0.339 Millimoles per liter Standard Deviation 0.3855
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 2; n=20, 19, 21	-0.8 Millimoles per liter Standard Deviation 1.41	-0.9 Millimoles per liter Standard Deviation 2.13	-0.5 Millimoles per liter Standard Deviation 1.66
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Anion gap; Day 5; n=7, 5, 7	1.0 Millimoles per liter Standard Deviation 1.73	0.4 Millimoles per liter Standard Deviation 1.67	-0.7 Millimoles per liter Standard Deviation 1.98
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 2; n=20, 19, 21	0.9 Millimoles per liter Standard Deviation 1.59	0.8 Millimoles per liter Standard Deviation 1.18	-0.1 Millimoles per liter Standard Deviation 2.10
Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Chloride, Phosphate, BUN, Triglycerides, Cholesterol, Anion Gap, Carbon Dioxide-Part 2 Carbon dioxide; Day 5; n=7, 5, 7	-1.0 Millimoles per liter Standard Deviation 2.00	-0.4 Millimoles per liter Standard Deviation 2.30	0.4 Millimoles per liter Standard Deviation 1.81